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Abstract 
Background: Feline immunodeficiency virus (FIV) is a global pathogen of Felidae species and a model system for 
Human immunodeficiency virus (HIV)‑induced AIDS. In felids such as the domestic cat (Felis catus), APOBEC3 (A3) 
genes encode for single‑domain A3Z2s, A3Z3 and double‑domain A3Z2Z3 anti‑viral cytidine deaminases. The feline 
A3Z2Z3 is expressed following read‑through transcription and alternative splicing, introducing a previously untrans‑
lated exon in frame, encoding a domain insertion called linker. Only A3Z3 and A3Z2Z3 inhibit Vif‑deficient FIV. Feline 
A3s also are restriction factors for HIV and Simian immunodeficiency viruses (SIV). Surprisingly, HIV‑2/SIV Vifs can 
counteract feline A3Z2Z3.
Results: To identify residues in feline A3s that Vifs need for interaction and degradation, chimeric human–feline A3s 
were tested. Here we describe the molecular direct interaction of feline A3s with Vif proteins from cat FIV and present 
the first structural A3 model locating these interaction regions. In the Z3 domain we have identified residues involved 
in binding of FIV Vif, and their mutation blocked Vif‑induced A3Z3 degradation. We further identified additional essen‑
tial residues for FIV Vif interaction in the A3Z2 domain, allowing the generation of FIV Vif resistant A3Z2Z3. Mutated 
feline A3s also showed resistance to the Vif of a lion‑specific FIV, indicating an evolutionary conserved Vif–A3 binding. 
Comparative modelling of feline A3Z2Z3 suggests that the residues interacting with FIV Vif have, unlike Vif‑interacting 
residues in human A3s, a unique location at the domain interface of Z2 and Z3 and that the linker forms a homeobox‑
like domain protruding of the Z2Z3 core. HIV‑2/SIV Vifs efficiently degrade feline A3Z2Z3 by possible targeting the 
linker stretch connecting both Z‑domains.
Conclusions: Here we identified in feline A3s residues important for binding of FIV Vif and a unique protein domain 
insertion (linker). To understand Vif evolution, a structural model of the feline A3 was developed. Our results show 
that HIV Vif binds human A3s differently than FIV Vif feline A3s. The linker insertion is suggested to form a homeo‑box 
domain, which is unique to A3s of cats and related species, and not found in human and mouse A3s. Together, these 
findings indicate a specific and different A3 evolution in cats and human.
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Background
APOBEC3 (A3) cytidine deaminases are anti-viral 
restriction factors containing either one or two zinc (Z)-
binding domains found in different clade-specific gene 
numbers and gene arrangements in placental mam-
mals [1–4]. For example, primates have seven genes 
(A3A–A3D, A3F–A3H), while cats encode four genes 
(A3Z2a–A3Z2c, A3Z3) [3, 5]. These A3 proteins target 
broadly viruses and mobile genetic elements that depend 
on reverse transcription, but also show antiviral activity 
against unrelated viruses (for recent reviews see [6, 7]). 
Some retroviruses express viral A3-counteracting pro-
teins, such as Vif of lentiviruses, Bet of foamy viruses, 
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the nucleocapsid of Human T cell leukemia virus type 1 
(HTLV-1), and the glycosylated (glyco)-Gag of Murine 
leukemia virus (MLV) [8–13]. The Vif protein prevents 
encapsidation of host-cell derived A3 proteins into nas-
cent viral particles. In the absence of Vif, encapsidated 
A3s inhibit lentiviruses during infection by deamination 
of cytidines in the single-stranded DNA formed during 
reverse transcription, by introducing G-to-A mutations 
in the coding strand. Additionally, some A3s inhibit virus 
replication by reducing reverse transcription and integra-
tion via non-editing mechanisms [14–19].
The domestic cat Felis catus (Fca) is the host to many 
diverse retroviruses, such as the lentivirus Feline immu-
nodeficiency virus (FIV), gammaretroviruses of the Feline 
leukemia virus (FeLV) group, and the spumaretrovirus 
Feline foamy virus (FFV) (for reviews see [20–23]). In a 
small proportion of naturally infected domestic cats, FIV 
causes an immunodeficiency disease similar to Human 
immunodeficiency virus type 1 (HIV-1)-induced AIDS 
[24]. However, highly pathogenic FIV isolates can cause 
mortality up to 60  % under experimental conditions 
[25–27]. Thus, FIV infection of cats is a valuable animal 
model to study HIV-1 and AIDS [28–30]. In addition to 
the domestic cat, species-specific FIVs that might cause 
disease in some natural hosts have been isolated in many 
Felidae [31]. FFVs replicate in domestic cats and in other 
Felidae and are not causing disease [32–34]. In contrast, 
FeLVs are pathogenic and induce in domestic cats seri-
ous diseases such as lymphomas and anemia [24], but are 
rarely found in other Felidae [31].
The domestic cat, and likely all other Felidae, encode 
four A3 genes, three closely related A3Z2 genes (A3Z2a, 
A3Z2b, A3Z2c) and one A3Z3 gene [4, 35]. Besides the 
four canonical A3 proteins, the cat genome can express, 
by read-through transcription and alternative splicing, 
a fifth A3 protein, namely the double-domain A3Z2Z3, 
with two detected variants A3Z2bZ3 and A3Z2cZ3 
(Fig.  1a). A3Z2Z3s are also found in big cats (Pantheri-
nae), indicating evolutionary conserved gene regulation 
[4, 36]. FIV Vif induces proteasome-dependent degra-
dation of feline A3Z2s, A3Z3, and A3Z2Z3 [4, 37]. The 
double-domain feline A3Z2Z3 contains two FIV Vif 
interaction regions, one in each Z-domain [36]. Inter-
estingly, and currently unexplained, FIVΔvif can be 
inhibited by feline AZ3 and A3Z2Z3, but not by A3Z2s 
[4, 36]. A reverse observation was made with FFVΔbet, 
where feline A3Z2s act as major inhibitors while A3Z3 
and A3Z2Z3 only moderately reduce the infectivity of 
FFVΔbet [4, 10, 38, 39]. Recent data indicate that certain 
polymorphisms in feline A3Z3 genes correlate with the 
susceptibility to FIV and/or FeLV infections [40].
FIV Vif induces the poly-ubiquitination of feline A3s and 
bridges A3s to an E3 ubiquitin ligase complex containing 
Cullin5 (Cul5), Elongin B/C (EloB/C), and RING-box 
protein RBX2 [37]; HIV-1 Vif forms a similar E3-ligase 
complex [41–43]. However, while HIV-1 Vif needs to addi-
tionally interact with the CBF-β protein to be stabilized 
and form this multiprotein complex [44, 45], FIV Vif does 
not bind CBF-β, and the FIV Vif-induced degradation of 
feline A3s does not require CBF-β to be expressed [46–
49]. HIV-1 Vif cannot counteract feline A3s, and HIV-1 
is therefore inhibited to various degrees by all feline A3s, 
with A3Z2Z3 displaying the strongest anti-HIV activity 
[36, 50–52]. The mechanistic reason preventing HIV-1 Vif 
from degrading feline A3s is unclear, especially because 
HIV-1 Vif and feline A3Z2Z3 are recovered together using 
co-immunoprecipitation assays [51]. In contrast to the Vif 
protein of HIV-1, Vif of Simian immunodeficiency virus 
from macaques (SIVmac) induces degradation of feline 
A3s [46, 51]. To assess the feasibility of generating an ani-
mal model for the human system based on FIV, we and 
others cloned FIV vif into HIV-1 and proved that in feline 
cell lines the A3 proteins are the dominant restriction fac-
tors against HIV-1 [36, 51].
In order to understand the FIV Vif interaction with 
feline A3 proteins, we identified in this study impor-
tant A3 residues and used a homology model of feline 
A3Z2Z3 to describe the structure–function relationship 
of these potential FIV Vif binding amino acids.
Results
FIV and HIV‑2/SIVmac/smm Vif induced degradation 
of felines A3s
In order to identify the molecular interaction of the FIV 
Vif protein and feline A3 proteins, we used FIV of domes-
tic cats (Felis catus, Fca), hereafter referred as FIV. Co-
transfection experiments of cat-derived A3s and FIV Vif 
expression plasmids were performed in 293T cells. All 
A3 constructs expressed the corresponding A3 protein 
as a C-terminal HA-tag, whereas Vif was expressed as a 
C-terminal V5-tag fusion protein. In addition, we also 
studied Vifs derived from HIV-1, HIV-2, SIVmac, and 
SIVsmm. Immunoblots of protein extracts from cells 
co-expressing both A3 and Vif were used as a read-out 
for degradation of the respective A3 protein. Results in 
Fig. 1b show that FIV Vif induces degradation of single-
domain feline A3Z2a, A3Z2b, A3Z2c, A3Z3, and dou-
ble-domain A3Z2bZ3 and A3Z2cZ3 in agreement with 
previous reports [4, 36, 37, 51]. The double-domain feline 
A3Z2bZ3 and A3Z2cZ3 were degraded by SIVmac Vif as 
seen before [46, 51], as well by the Vifs of SIVsmm and 
HIV-2. For subsequent experiments we used the expres-
sion plasmid FcaA3Z2bZ3, hereafter referred to as feline 
A3Z2Z3 for simplicity.
To understand, whether FIV Vif binds directly to 
feline A3s, we expressed A3Z2 and A3Z3 as GST fusion 
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proteins in E. coli. Recombinant A3s were purified by 
affinity chromatography and mixed with lysates of 293T 
cells expressing FIV Vif. Following GST pulldown, immu-
noblots showed Vif binding to GST-A3Z2 and to GST-
A3Z3 but not to GST (Fig. 1c). We further explored the 
interaction of FIV Vif with feline A3s by analyzing the 
cellular distribution in co-expressing cells. HOS cells 
were transfected either with plasmids encoding for feline 
A3Z2, A3Z3, or A3Z2Z3 alone or together with a plas-
mid encoding for FIV Vif-TLQAAA. The TLQ to AAA 
mutation in the Vif putative BC-box prevents its interac-
tion with the E3 complex [37]. Feline A3 proteins showed 
a mostly cytoplasmic localization with no or very little 
nuclear A3, and feline A3Z3 localized in addition to the 
nucleoli (Additional file  1: Fig. S1, compare to Fig. S4). 
Nucleolar localization of A3Z3 proteins derived from 
humans and horses had been described before [53]. Very 
similar to the A3s, FIV Vif-TLQAAA showed a cyto-
plasmic distribution with little presence in the nucleus. 
Under these experimental conditions, strong co-locali-
zation of Vif and A3s was detected in cytoplasmic areas 
near the nucleus (Additional file 1: Fig. S1).
Identification of feline A3Z3 residues important for FIV Vif 
induced degradation
Feline A3Z3 and A3Z2Z3 are the restriction factors for 
FIVΔvif, whereas A3Z2s are not active against FIVΔvif 
[4, 36, 37, 51]. To characterize the Vif interaction with 
residues in feline A3Z3, A3Z3s derived from humans 
(A3H haplotype II, HsaA3H) and big cats (tiger, Pan-
thera tigris, Pti; lion, Panthera leo, Ple; lynx, Lynx lynx, 
Lly; puma, Puma concolor, Pco) (protein alignments are 
highlighted in Additional file 1: Fig. S2) were used in co-
transfection experiments with FIV Vif. A3s derived from 
tiger, lion, lynx, and puma were efficiently degraded by 
FIV Vif (Fig. 2a). Because A3H was resistant to FIV Vif-
induced degradation, the construction of Hsa–Fca chi-
meric A3Z3s promised a rational approach to identify the 
A3Z3/FIV-Vif binding region. The chimeras Z3C1 and 
Z3C2 spanned respectively amino acids 1–22 and 1–50 
of feline A3Z3, with the remaining part being derived 
from A3H, whereas Z3C6 and Z3C7 were mostly feline 
A3Z3 with residues 1–22 or 1–50 derived from A3H 
(Fig.  2b). Among the four A3Z3 chimeras, Z3C2 and 


























Fig. 1 The interaction of feline APOBEC3s with FIV Vif. a Representation of APOBEC3 (A3) genes in the genome of Felis catus, chromosome (chr.) 
B4. Coding regions of the A3 genes (A3Z2a, A3Z2b, A3Z2c, A3Z3) shown as arrows. Red rectangle exon 2 of A3Z3 that is untranslated in the A3Z3 
mRNA, however translated (“linker domain”) in readthrough transcripts A3Z2bZ3 and A3Z2cZ3. Spliced‑out introns (dashed lines) are indicated, 
mRNAs for A3Z2s and A3Z3 not shown. For details, see references [4, 36]. b 293T cells were transfected with expression plasmids for FcaA3Z2a, 
FcaA3Z2b, FcaA3Z2c, FcaA3Z3, FcaA3Z2bZ3 and FcaA3Z2cZ3 together with HIV‑1, SIVmac, HIV‑2 and SIVsmm or FIV Vif or no Vif (replaced by 
pcDNA3.1). FcaA3s, Vifs and tubulin were visualized by immunoblot using anti‑HA, anti‑V5 and anti‑tubulin antibodies. c Immunoprecipitation of E. 
coli expressed FcaA3Z2 and ‑Z3 (GST fusion proteins) after mixing with 293T‑derived FIV Vif (Vif‑V5). Asterisk indicates the impression of GST blob on 
the blot and Dagger denotes for a possible degradation product of FcaA3Z3
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and Z3C7 showed resistance to degradation (Fig.  2c). 
HIV-1 Vif (derived from clones NL4-3 or LAI) could not 
degrade any of the A3Z3 chimeras, but LAI Vif degraded 
A3H as reported before [54], and SIVmac Vif degraded 
Z3C1 and A3H but not Z3C2, Z3C6 and Z3C7 (Fig. 2c).
Our findings indicate that feline-derived residues 
shared by Z3C2 and Z3C6 (positions 23–50) are essen-
tial for FIV Vif interaction. This A3 stretch contained a 
number of positions evolving exclusively under purifying 
selection, for both carnivores and for primates (Fig. 2d). 
Globally, diversity among A3Z3 from carnivores was 
higher than among the primates’ orthologs (respectively 
0.24  ±  0.02 vs 0.054  ±  0.007, overall average pairwise 
nucleotide distance  ±  bootstrap standard error esti-
mate) (Additional file  1: Fig. S3A). During this analysis, 
we identified for the first time duplicated A3Z3s in the 
same genome (i.e. in-paralogs [55]) retrieved from differ-
ent lineages within Caniformia (Ursidae, the giant panda 
and the polar bear; Phocidae, the Weddell seal; and Odo-
benidae, the walrus) but we could neither identify the 
two A3Z3 in-paralogs in Canidae (dog) nor in Mustelidae 
(ferret) genomes. By contrast, in all Felidae genomes that 
we have screened we could only identify one of these in-
paralogs (Additional file 1: Fig. S3A).
The A3Z3 region position 23–50 differs in 16 amino 
acids between human and feline A3Z3s, and contains 
certain highly conserved amino acid positions (Fig.  2b, 
d). We mutated thus most feline-specific residues in 
feline A3Z3, in positions 35–38 and 40–48. Residues in 
position 35 +  36 (KL), 37 +  38 (PE), 41 +  42 (LI) and 
43 (H) in A3Z3 were substituted by the correspond-
ing ones found in A3H. Additionally, we exchanged the 
A3Z3 residues at position 45 +  46 (DC), 47 +  48 (LR) 
and 41  +  42 (LI) against AA (Fig.  3a). These mutated 
A3s were characterized for resistance to degradation by 
co-expression with FIV Vif. We found that only A3Z3s 
mutated at position 41  +  42 (LI ≫  TP and LI ≫  AA) 
showed partial resistance to degradation by Vif (Fig. 3b). 
A65I in feline A3Z3 has been described in Brazilian 
cats and discussed to be a relevant resistance mutation 
against FIV [40, 56]. Under our experimental conditions, 















Fig. 2 Identification of residues in FcaA3Z3 for FIV Vif induced degradation. a Expression plasmids for FcaA3Z3, HsaA3H and big cat A3Z3s were co‑
transfected with FIV Vif into 293T cells. Cell lysates were analyzed by immunoblot. A3s contain a C‑terminal HA‑tag, Vifs contain a C‑terminal V5‑tag. 
FcaA3s represent domestic cat (Felis catus) APOBEC3s. Pti, Ple, Lly and Pco represent Panthera tigris corbetti; Panthera leo bleyenberghi; Lynx lynx; Puma 
concolor. b Scheme of FcaA3Z3/HsaA3H.hapII chimeras (Z3C1, ‑C2, –C6, ‑C7). Highlighted sequence diversity between HsaA3H and FcaA3Z3 in an 
N‑terminal region. c 293T cells were co‑transfected with expression plasmids for FcaA3Z3, Z3C1, Z3C2, Z3C6, Z3C7 or HsaA3H hapII and FIV Vif, HIV‑1 
(NL4‑3 or LAI) or SIVmac Vif. The expression of chimeras and Vif proteins were detected by using anti‑HA and anti‑V5 antibodies, respectively. Tubulin 
served as loading control. d Amino acid logo for the N‑terminus in 15 A3Z3 sequences from ten Carnivores species (upper panel) and for eight A3Z3 
sequences from eight Primates species (lower panel). Residues identified to evolve under purifying selection are labelled with “pur”. No residue was 
identified to evolve under diversifying selection in this A3Z3 stretch
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resistance to Vif-mediated degradation (Fig.  3c). How-
ever, very important, the combination of mutations, A65I 
and L41A-I42A, resulted in an A3Z3 variant that showed 
complete resistance to FIV Vif degradation (Fig. 3c). We 
wondered whether experimental overexpression of the 
V5-tagged FIV Vif could mask the potency of the natural 
A65I variant to resist degradation. To address this ques-
tion, we used as a source for Vif expression the replica-
tion-deficient FIV packaging construct pCPRΔenv [57]. 
Expression of increasing levels of pCPRΔenv in the pres-
ence of constant amounts of A3 revealed that the A65I 
mutation was degraded less efficiently than the wild-type 
A3Z3 (Fig.  3d). As a control we used A3C and A3Z3.
A65I  +  LI-AA, which both showed no degradation by 
Vif derived by pCPRΔenv. Together, these findings indi-
cate that the A65I mutation in feline A3Z3 mediates a 
partial protection, and that a combination with L41A-
I42A resulted in enhanced resistance to Vif.
The stretch involved in the interaction with Vif encom-
passed a number of highly conserved residues between 
A3Z3s from carnivores and primates, as well as residues 
under purifying selection (Fig. 2d). The L41–I42 residues 
in cat A3Z3 identified to interact with Vif are strictly con-
served (L|I) in A3Z3 from felids, to the extent that even 
the codons used are also strictly conserved (CTT|ATT) 
for the five Felidae species analyzed. Interestingly, the 
two A3Z3 paralogs in Caniformia display different amino 
acid profiles in this Vif-binding region (Additional file 1: 
Fig. S3A), and albeit chemically related, amino acid resi-
dues in these positions are variable (I/L/V|I/T). Finally, 
this A3Z3 stretch is very different in the corresponding 
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Fig. 3 Generation of FIV Vif resistant FcaA3Z3. a Representation of FcaA3Z3 protein. Residues investigated are shown. CD cytidine deaminase 
domain. b, c Several mutants at N‑terminal region of FcaA3Z3 were generated. To analyze the sensitivity of FcaA3Z3 mutants to FIV Vif, 293T cells 
were co‑transfected with expression plasmids for FcaA3Z3 wild‑type (FcaA3Z3) or indicated mutants and FIV Vif. 48 h later, FcaA3Z3, Vif and tubulin 
proteins were detected by immunoblot. d Increasing amounts of FIV gag‑pol‑vif helper plasmid pCPRΔenv that expresses virus‑typical levels of FIV 
Vif without a tag were analyzed for degradation of HsaA3C, FcaA3Z3, FcaA3Z3.A65I and FcaA3Z3.A65I + LI‑AA. 293T cells were co‑transfected with 
150 ng HsaA3C, FcaA3Z3, or A3Z3 mutants and pCPRΔenv (0, 10, 50, 150 or 250 ng). 48 h later, A3 expression was analyzed by immunoblots by 
using anti‑HA antibody. Anti‑FIV p24 detected expression of FIV helper plasmid pCPRΔenv, tubulin detection confirmed equal protein loading
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evolutionary relationships for these two residues could 
thus at least partly explain species-specificity of the inter-
action between felidae A3Z3 and FIV Vif, reflecting adap-
tation and specific targeting.
Generation of a FIV Vif resistant feline A3Z2Z3
Our results demonstrate that feline A3Z2 can also be 
efficiently degraded by FIV Vif, thus implying a specific 
interaction between both proteins (Fig.  1b). In order 
to generate an A3Z2Z3 protein resistant to FIV Vif, we 
decided to mutate as well the A3Z2 moiety. To identify 
residues important for FIV Vif interaction with feline 
A3Z2, chimeric A3s of A3Z2 and human A3C, called 
Z2C1, -C4, -C5 and -C30 (Fig. 4a), were co-expressed with 
FIV Vif. The chimeras Z2C1, Z2C4 and Z2C5 spanned 
the 1–22, 1–131 and 1–154 amino acids of feline A3Z2, 
respectively, the remaining parts being derived from A3C. 
Chimera Z2C30 was feline A3Z2, with amino acids 132–
154 derived from A3C. Chimeras Z2C1 and Z2C4 showed 
moderately reduced protein levels when FIV Vif was 
co-expressed, chimera Z2C5 resistance to degradation, 
and chimera Z2C30 was efficiently degraded by FIV Vif 
(Fig. 4b). As controls, we investigated all chimeras for deg-
radation by HIV-1 and SIVmac Vifs. HIV-1 Vif induced 
degradation of Z2C1 only, and SIVmac Vif completely 
degraded Z2C1, Z2C4 and Z2C30, and mostly Z2C5 
(Fig. 4b). Because the Z2C5 chimera, in which the C-ter-
















Fig. 4 FIV Vif requires C‑terminal FcaA3Z2 (A3Z2b) residues for A3 degradation. a Scheme of A3Z2/A3C chimeras (Z2C1, ‑C4, ‑C5, ‑C30). Highlighted 
are C‑terminal sequence differences between FcaA3Z2 and HsaA3C. b 293T cells were co‑transfected with expression plasmids for Z2C1, Z2C4, 
Z2C5 or Z2C30 and FIV Vif, HIV‑1 or SIVmac Vif. A3s contain a C‑terminal HA‑tag; Vifs contain a C‑terminal V5‑tag. The expression of chimeras and 
Vif proteins were detected by using anti‑HA and anti‑V5 antibodies, respectively. Cell lysates were also analyzed for equal amounts of total proteins 
using the anti‑tubulin antibody. c Expression plasmids for A3C, FcaA3Z2, and big cat A3Z2s were co‑transfected with FIV Vif into 293T cells. 48 h 
later, cells were analyzed by immunoblot. The expression of A3 and Vif proteins were detected by using anti‑HA and anti‑V5 antibodies, respec‑
tively. FcaA3s represent domestic cat (Felis catus); Pti, Ple, and Lly represent Panthera tigris corbetti; Panthera leo bleyenberghi; Lynx lynx, varI, variant I. 
d Amino acid logo for the C‑terminus in 17 A3Z2 sequences from 12 Carnivores species (upper panel) and for 51 A3Z2 sequences from 17 Primates 
species (lower panel). Residues identified to evolve under purifying or diversifying selection are respectively labelled with “pur” (black) or with “div” 
(red)
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Vif, we speculated that the C-terminal region of cat A3Z2 
could be important for FIV Vif-induced degradation. 
SIVmac Vif, which cannot degrade feline A3Z2 (Fig. 4b), 
interacts presumably with C-terminal human-derived 
sequences spanning A3C sequences present in Z2C5 and 
Z2C30 (Fig. 4b). In addition we analyzed the degradation 
sensitivity of A3Z2 proteins from big cats and found that 
FIV Vif did not induce degradation of A3Z2 from tiger, 
lion or lynx (Fig.  4c). These felid A3Z2s are very similar 
to FcaA3Z2 as they share 89–93 % identically conserved 
residues (Additional file 1: Figs. S2, S3B, Fig. 4d), whereas 
cat A3Z2 and human A3C are much more diverse and 
share only 47 % identical amino acids. Thus, we identified 
four positions in which all big cat A3Z2s differed from 
FcaA3Z2, in positions N18, T44, D165 and H166 (Addi-










Fig. 5 FcaA3Z2 and FcaA3Z2Z3 mutations block degradation by feline Vifs. a Representation of FcaA3Z2b protein. Residues investigated are shown. 
CD cytidine deaminase domain. Residues different found in A3Z2 of the domestic cat and big cats indicated. Pti, Ple, and Lly represent Panthera 
tigris corbetti; Panthera leo bleyenberghi; Lynx lynx. b Expression plasmids for FIV Vif and FcaA3Z2, PtiA3Z2 or several mutants of feline A3Z2 were co‑
transfected into 293T cells. The expression of A3 and Vif proteins were detected by using anti‑HA and anti‑V5 antibodies, respectively. c FcaA3Z2Z3‑
M that contains DH‑YN and A65I + LI‑AA mutations in Z2‑ and Z3‑domains was analyzed. Expression plasmids for FcaA3Z2Z3 wild‑type or 
FcaA3Z2Z3‑M were transfected together with FIV Vif plasmid into 293T cells. 48 h later, immunoblots were used to detect the expression of A3 and 
Vif by anti‑HA and anti‑V5 antibodies, respectively. d Vif from lion‑derived FIV (FIVple) degrades wild‑type FcaA3s (from domestic cat) and PleA3Z2 
(from lion). 293T cells were co‑transfected with expression plasmids for wild‑type FcaA3Z2, PleA3Z2, FcaA3Z3 and FcaA3Z2Z3 and FIVple Vif. 48 h 
later, cells were harvested and lysates were used for detecting the expression of Vif and A3s by anti‑HA and anti‑V5, respectively. Cell lysates were 
also analyzed for equal amounts of total proteins using the anti‑tubulin antibody. e Expression plasmids for FcaA3s with mutations (FcaA3Z2.DH‑YN, 
FcaA3Z3.A65I + LI‑AA or FcaA3Z2Z3‑M) were co‑transfected with lion FIV Vif (FIVple Vif ) or domestic cat FIV Vif (FIVfca Vif ) and 48 h later, cell lysates 
were used for detecting FcaA3s, Vif, and tubulin by anti‑HA, anti‑V5 and anti‑tubulin, respectively. Fca, Felis catus; Ple, Panthera leo bleyenberghi
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position 18 (N18K) and 44 (T44R) in FcaA3Z2, but 
found both mutants to be efficiently degraded by FIV Vif 
(Fig.  5b). Very similar, A3Z2.D165Y was depleted when 
co-expressed with FIV Vif. Interestingly, mutation of 
residue 166 (H166N) generated a partially Vif-resistant 
A3Z2 protein. We speculated that the adjacent D165 
might enhance the Vif-resistance seen in the H166N 
variant. Indeed, the A3Z2.DH-YN mutant showed com-
plete resistance to FIV Vif (Fig.  5b). We also analyzed 
tiger A3Z2.Y165D but could not reverse the resistance 
to degradation by FIV Vif (Fig.  5b). We conclude that 
D165-H166 in the C-terminal region of cat A3Z2 are 
important for Vif-mediated degradation together with 
other residues that remain to be characterized.
Finally, we constructed A3Z2Z3-M containing D165Y, 
H166N in Z2 and A65I + L41A, I42A in Z3. Co-expres-
sion experiments of A3Z2Z3-M with FIV Vif showed 
that this A3 variant was Vif-resistant (Fig.  5c). Impor-
tantly, the mutations that generated Vif-resistance did 
not impact the subcellular localization of the feline A3, 
as demonstrated by confocal microscopy of transiently 
transfected HOS cells (Additional file 1: Fig. S4). We also 
studied lion specific FIV (FIVple) Vif, which shares only 
52 % identical residues with domestic cat FIV Vif (Addi-
tional file 1: Fig. S2C). FIVple Vif was able to induce deg-
radation of PleA3Z2 and of FcaA3Z2, A3Z3 and A3Z2Z3 
(Fig. 5d). Interestingly, FIVple Vif could not induce deg-
radation of the mutated cat A3s A3Z2.DH-YN, A3Z3.
A65I  +  LIAA and A3Z2Z3-M (Fig.  5e). These findings 
suggest that Vifs from lion and from domestic cat FIVs 
interact with identical residues in the domestic cat A3s.
To check whether the FIV Vif-resistant mutant A3s dis-
played modified binding to Vif, wild-type and mutated 
A3s together with FIV Vif-TLQAAA were co-expressed 
and analyzed by anti-HA immuno-precipitation (Fig. 6). 
Wild-type cat A3Z3 precipitated FIV Vif (Fig.  6a), con-
sistent with a direct interaction of both proteins (Fig. 1c). 
Only very little Vif bound to A3Z3.A65I and no Vif was 
detected in precipitations of A3Z3.LI-AA and A3Z3.
A65I  +  LI-AA (Fig.  6a). However, when we examined 
wild-type A3Z2 and the DH-YN mutant, we detected 
similar amounts of Vif in both precipitations. Wild-
type A3Z2Z3 bound high levels of Vif, and this binding 
was much reduced by the mutated variant A3Z2Z3-M 
(Fig.  6b). Globally, our observations suggest that A65I 
and LI-AA mutations in A3Z3 abolished FIV Vif binding, 
while hitherto not identified residues mediate Vif binding 
in A3Z2.
Structural analysis of feline A3Z2Z3
To identify the position of residues in feline A3s that, 
when mutated, prevent binding of FIV Vif and A3Z2Z3 
degradation, a structural model of feline A3Z2Z3 was 
generated, initially aligning its sequence to the human 
full-length A3G model [58]. Surprisingly, the alignment 
indicated a large insertion in the Z2–Z3 linker region 
in the feline sequence that is not present in the human 
counterpart (Additional file  1: Fig. S5). This domain 
insertion spans 46 residues, extending the feline A3Z2Z3 
linker to 83 residues compared to 27 residues in humans. 
The structure of the 83-residue linker was predicted using 
TopModel [59, 60]. Although the five identified tem-
plate structures show only a low sequence identity with 
respect to the linker (up to 19.4  %; see “Methods” sec-
tion), they all share a homeo-box domain fold [61]. The 
best three templates were aligned to the linker sequence 
Fig. 6 Differential binding of FIV Vif to wild‑type and mutant feline A3s. a Expression plasmids for FcaA3Z3s wild‑type and mutants (all with HA‑tag) 
and FIV Vif‑TLQAAA (V5 tag) were co‑transfected into 293T cells. The proteins were immunoprecipitated by α‑HA beads and analyzed by immuno‑
blots using anti‑HA and anti‑V5 antibodies. b Expression plasmids for FcaA3s (FcaA3Z2, FcaA3Z2.DH‑YN, FcaA3Z2Z3 and FcaA3Z2Z3‑M, all with HA‑
tag) and FIV Vif‑TLQAAA (V5‑tag) and were co‑transfected into 293T cells, pcDNA3.1 (+) served as an A3‑free control. 48 h later, cells were harvested, 
proteins were immunoprecipitated by α‑HA beads. The FcaA3s and FIV Vif proteins were detected by anti‑HA and anti‑V5 antibodies, respectively
Page 9 of 23Zhang et al. Retrovirology  (2016) 13:46 
(Additional file 1: Fig. S5) and used for structure predic-
tion. The rest of the feline A3Z2Z3 protein was predicted 
using the homology model of human A3G [58] as a tem-
plate. Finally, the linker domain and the rest of the feline 
A3Z2Z3 protein were manually docked, sequentially 
connected, and unstructured parts of the linker domain 
were energy minimized (Fig.  7a). While this cannot be 
expected to result in an exact structural model, it pro-
vides a representation where the linker domain inser-
tion could be located with respect to the rest of the feline 
A3Z2Z3 protein.
The five residues in feline A3s that, when mutated, pre-
vent binding of FIV Vif and A3Z2Z3 degradation (D165, 
H166, L285, I286, A309; the last three corresponding to 
L41, I42 and A65 of A3Z3), are located opposite to the 
putative location of the linker domain and are at the 
boundary between the Z2 and Z3 domains (Fig. 7b). The 
predicted HIV-1 Vif binding regions in human A3G, 
A3C and A3H are additionally depicted in Fig.  7b–d, 
respectively. For A3C and A3H, the predicted HIV-1 
Vif binding regions are spatially clearly separated from 
the respective five residues identified here in feline A3s 
(Fig.  7c, d). One may thus speculate that our findings 
indicate a FIV Vif binding region in feline A3 different 
from the ones described for HIV-1 Vif in human A3s.
FIV Vif‑resistant feline A3s are antiviral
In the next set of experiments, we investigated whether 
feline A3s carrying the putative Vif-binding mutations 
displayed antiviral activity and resistance against Vif in 
FIV infections. We generated FIV luciferase reporter 
viruses by co-expression with either no A3 or with A3Z3, 
A3Z3.A65I, A3Z3.LI-AA or A3Z3.A65I  +  LI-AA and 
increasing levels of the FIV Vif plasmid (0–160 ng). Vec-
tor particles were normalized for reverse transcription 
(RT) activity, and luciferase activity was quantified 2 days 
post infection (Fig. 8a). All feline A3Z3s, either wild-type 
or mutants, were able to inhibit to the same extent Vif-
deficient FIV, demonstrating that the described muta-
tions do not hinder the potential for antiviral activity. 
Wild-type feline A3Z3 was fully counteracted by the 
lowest amount of Vif plasmid (40  ng) (Fig.  8a), match-
ing well complete degradation observed in the lysates of 
FIV-producing cells (Fig.  8b). Opposite to the homog-
enous behavior in the absence of Vif, mutated A3Z3s 
showed variable resistance to Vif-counteraction, as was 
obvious in the levels of remaining A3 signal in the cell 
lysates of the FIV-producing cells (Fig.  8b). Intermedi-
ate amounts of vif-encoding plasmid (40–80  ng) par-
tially counteracted the inhibition of A3Z3.A65I or A3Z3.
LI-AA mutants, and higher levels of Vif (160 ng plasmid) 
recovered infectivity of FIVs produced in the presence of 
A3Z3.A65I and A3Z3.LI-AA. However, even the high-
est levels of Vif were not able to counteract the antiviral 
activity of A3Z3.A65I +  LI-AA (Fig.  8a, b). The impor-
tance of Z2- and Z3-mutations in feline A3Z2Z3-M was 
characterized with 100 ng of FIV Vif plasmid. FIV lucif-
erase viruses were produced and examined as described 
above using A3Z2Z3 and A3Z2Z3-M. FIV Vif restored 
the infectivity to levels similar to those in the absence of 
A3Z2Z3, while A3Z2Z3-M strongly inhibited FIV, either 
with or without Vif expression (Fig.  8c). The immunob-
lots of the corresponding FIV producing cells confirmed 
protein expression and Vif-dependent degradation of the 
wild-type A3Z2Z3 protein (Fig. 8d). To explore whether 
stable expression of A3Z2Z3-M can impact spread-
ing infection, human HOS.CD4.CCR5 cells expressing 
either wild-type or mutated A3Z2Z3 were established 
(Fig. 8e, Additional file 1: Fig. S6) and infected by HIV-1 
expressing FIV Vif (HIV-1vifFIV) [36]. FIV could not be 
investigated directly, because there are no feline cell lines 
known to be negative for A3 expression, and FIV cannot 
replicate in human cell lines. Whereas HIV-1vifFIV was 
detected at day six in the supernatant cells with wild-type 
A3Z2Z3, HOS cells expressing the A3Z2Z3-M showed 
a much delayed kinetic of viral replication (Fig. 8f ). This 
observation suggests that the engineered A3Z2Z3-M 
protein also gained the capacity to restrict FIV Vif during 
multi-rounds of replication.
Encapsidation of A3 proteins in nascent virions is 
required for their antiviral activity. We investigated first 
whether mutated feline A3s could be differentially encap-
sidated into nascent virions. For this, we produced Vif-
deficient FIV particles during expression of the different 
A3 proteins, measured the differential infectivity of the 
particles (Additional file 1: Fig. S7A) and subjected virus 
lysates to immunoblot analysis (Additional file  1: Fig. 
S7B). Results showed that wild-type and mutated feline 
A3s were detected in the concentrated FIVs (VLPs). How-
ever, while wild-type A3Z3 was less efficiently packaged 
compared with the A3Z3.A65I  +  LI-AA mutant, the 
wild-type A3Z2Z3 was detected in virions in higher abun-
dance than the A3Z2Z3-M variant (Additional file 1: Fig. 
S7B). We addressed then the question whether encapsi-
dated mutated feline A3s effectively exerted their cytidine 
deaminase activity onto the FIV genome in the virion. 
To tackle this question, cells were infected with FIV pro-
duced during cellular expression of feline A3Z3, A3Z3.
A65I  +  LI-AA, A3Z2Z3 or A3Z2Z3-M, in the absence 
of A3 expression as a negative control, or during expres-
sion of human A3G as positive control. Total DNA was 
isolated from infected cells and subjected to differential 
DNA denaturing PCR (3D-PCR) [62] on the viral vec-
tor encoded luciferase gene 12 h post infection. Based on 
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the overall nucleotide content, 3D-PCR amplifies PCR 
products at different denaturing temperatures (Td), with 
amplicons with higher A  +  T content displaying lower 
denaturing temperatures than amplicons with higher 
G  +  C content. The net effect of the cytidine deami-
nase A3 activity is thus expected to lower the denaturing 
Fig. 7 Composite model of feline APOBEC3 and locations of residues mediating Vif binding. a Structural model of FcaA3Z2Z3 including the linker 
(pink) at a putative location above the Z2 (yellow) and Z3 (blue) domains; the linker connections to the Z2 and Z3 domains are highlighted by 
dashed lines. [69]. b Structural model of FcaA3Z2Z3 rotated by 90° with respect to a (Z2 domain: yellow; Z3 domain: blue; the linker region and parts 
of the N‑terminus of Z2 and the C‑terminus of Z3 for which no structure could be modeled were omitted for clarity). Residues in sphere representa‑
tion in yellow (D165/H166), those in blue (L285/I286/A309), and those in orange (D131‑Y134). Residues sequentially equivalent to the latter in the sol‑
uble N‑terminal Vif‑binding domain (sNTD) of A3G (PDB ID 2MZZ; pale green) are colored in green; these residues are part of the Vif‑binding regions 
of the sNTD [68]. c Crystal structure of human A3C (PDB ID: 3VOW) and structural model of feline A3Z2b depicting the positions of respective HIV‑1 
Vif and FIV Vif binding sites. The domains are orientated as the Z2 domain in a. d Structural model of human A3H‑HapII and feline A3Z3 depicting 
the positions of respective HIV‑1 Vif and FIV Vif binding sites. The domains are orientated as the Z3 domain in a. Key residues involved in Vif binding 
are labelled (except human A3C), represented in sticks and highlighted with its surface in orange color
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temperature of the target DNA, leading to lower Tds val-
ues. Indeed, FIV virions produced in the absence of A3s 
yielded 3D-PCR products with the lowest Td of 86.3  °C, 
whereas all FIV virions produced during A3 expression 
resulted in 3D-PCR products with decreased Tds (as low 
as 84.2 °C) (Additional file 1: Fig. S7C). This indicates that 
the wild-type and mutant feline A3s display enzymatic 
deamination activities.
Fig. 8  The impact of mutations in FcaA3s on FIV infectivity. a FIVΔvif luciferase reporter virions were produced in the presence of feline A3 expres‑
sion plasmids (FcaA3Z3 wild‑type, FcaA3Z3.A65I, FcaA3Z3.LI‑AA or FcaA3Z3.A65I + LI‑AA, 250 ng plasmid) with increasing amounts of FIV Vif (0, 40, 
80 and 160 ng plasmid), pcDNA3.1 (+) was added as a control (vector). Infectivity of reporter vectors was determined by quantification of luciferase 
activity in 293T cells transduced with vector particles. b Cell lysates of FIV producer cells examined in a were used to detect the expression of 
FcaA3Z3 and FIV Vif by anti‑HA and anti‑V5 antibodies, respectively. Cell lysates were also analyzed for equal amounts of total proteins using anti‑
tubulin antibody. c The impact of FcaA3Z2Z3 and FcaA3Z2Z3‑M on infectivity of FIVΔvif luciferase reporter vectors in the presence of FIV Vif. 293T 
cells were co‑transfected FIVΔvif luciferase reporter viruses with 1000 ng FcaA3s and 100 ng FIV Vif expression plasmids. 48 h later, FIV particles were 
used to infect 293T cells, and infectivity was determined by quantification of luciferase activity. d Cell lysates for FIV producer cells used in c were 
analyzed by immunoblots to detect the expression of FcaA3Z3s and FIV Vif by anti‑HA and anti‑V5 antibodies, respectively. Cell lysates were also 
analyzed using anti‑tubulin antibody. e, f Spreading replication of HIV‑1 expressing FIV Vif (NL‑Bal.vifFIV) is inhibited by feline A3Z2Z3‑M. e Immuno‑
blot analysis of HOS.CD4.CCR5 cells stable expressing feline A3Z2Z3 proteins. A3 proteins were detected by anti‑HA antibody. Anti‑tubulin served 
to demonstrate equal protein loading. f HOS.CD4.CCR5 cells expressing either wild‑type A3Z2Z3 or A3Z2Z3‑M were infected by NL‑Bal.vifFIV with 
an MOI of 0.01 and virus replication was monitored by using the cell culture supernatant for infection of TZM‑bl luciferase reporter cells. Asterisks 
represent statistically significant differences: ***p < 0.001; **0.001 < p < 0.01; *0.01 < p < 0.05; ns, p > 0.05 (Dunnett t test)
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The linker in feline A3Z2Z3 is targeted by HIV‑2 
and SIVmac/smm Vifs
We and others have observed that SIVmac Vif can 
induce degradation of feline A3Z2Z3 (Fig.  1b) [46, 
51]. Figure  1b demonstrates that the Vifs of SIVsmm 
and HIV-2 also display this phenotype and are able to 
degrade feline A3Z2Z3. To elucidate this unexpected 
capacity of primate lentiviruses to counteract feline A3s 
in the context of viral infections, we generated luciferase 
reporter viruses for SIVmac and HIV-2 (Fig.  9). SIV-
mac or SIVmacΔvif luciferase reporter viruses [63] were 
produced in the absence or presence of human A3G, 
feline A3Z2a, A3Z2b, A3Z2c, A3Z2bZ3, A3Z2cZ3 or 
A3Z2bZ3s that included polymorphic residues found in 
exon 4 of different F. catus breeding lines (Birman, Japa-
nese Bobtail, British Shorthair, Turkish Van [36]). The Vif 
proficient virus SIVmac-Luc expresses Vif in its natural 
expression context; however Vif lacks a tag for detection. 
Viral particles were normalized for RT activity and lucif-
erase activity of infected cells was quantified 2 days post 
infection (Fig.  9a). We found that double-domain feline 
A3s strongly inhibited Vif-deficient SIVmac, and that Vif 
expression fully counteracted this antiviral activity, show-
ing therefore a similar pattern to human A3G. However, 
Vif expression did not affect inhibition of SIVmac by sin-
gle domain A3s (Fig. 9a). The corresponding immunob-
lots of the virus producing cells showed Vif-dependent 
degradation of human A3G and of all feline A3Z2Z3s 
inspected. Feline A3Z2s and A3Z3 displayed a resistance 
to degradation by Vif proficient SIVmac (Fig.  9c). We 
performed a similar experiment using a HIV-2 luciferase 
reporter virus [64], which is a three-plasmid lentiviral 
vector system that requires Vif to be co-expressed from 
a separate plasmid (Fig. 9b). Using this system, we found 
that HIV-2 Vif counteracted the antiviral activity of 
human A3G, feline A3Z2bZ2 and of A3Z2cZ3. Again, the 
antiviral activity of feline single-domain A3s could not be 
inhibited by HIV-2 Vif (Fig. 9b). The immunoblots of the 
virus producing cells showed a Vif-dependent depletion 
of human A3G as well as of the feline double-domain A3s 
(Fig. 9d).
The Vif-mediated degradation profile exclusive to 
A3Z2Z3s may indicate that the HIV-2/SIVmac/smm Vifs 
require for interaction with the feline A3Z2Z3 a pro-
tein domain that is absent in the single-domain A3Z2 or 
A3Z3. We speculated that the homeo-box domain inser-
tion (linker region) could play a central role in these Vif 
interactions. To test our hypothesis, three constructs 
were assayed: an A3Z2Z3 in which the linker was deleted 
(ΔLinker); and two versions of A3Z2Z3 in which either 
residues 223–240 (Δ222) or residues 211–240 (Δ210) in 
the linker were removed (Fig. 10a). All these constructs 
successfully expressed protein upon transfection, and 
FIV Vif was able to degrade all of them. Only the linker 
truncations Δ222 and Δ210 were efficiently degraded 
by Vif of HIV-2/SIVmac/smm, whereas the ΔLinker 
construct showed very little degradation (Fig.  10b). We 
extended this experiment and analyzed the degradation 
with increasing levels (0, 20, 50, 150 or 250  ng) of SIV-
mac or HIV-2 Vif expression plasmid (Additional file  1: 
Fig. S8). Interestingly, the A3Z2Z3 lacking the linker 
domain (ΔLinker) showed dose-dependent moder-
ate degradation, while mutants Δ222 and Δ210 showed 
a HIV-2/SIV Vif-dependent degradation similar as the 
wildtype A3Z2Z3 protein (Fig. 10b, Additional file 1: Fig. 
S8). To characterize the linker mutant A3s for functional 
antiviral activity, FIVΔvif and SIVmacΔvif luciferase 
reporter viruses were generated in the presence of wild-
type and mutated A3s (Fig. 10c, d, Additional file 1: Fig. 
S9). Immunoblots of the viral particles showed that all 
A3s were encapsidated (Additional file  1: Fig. S9). Con-
sistently in both viral systems, A3Z2Z3 moderately lost 
antiviral activity when part or the complete linker was 
deleted (ΔLinker, Δ210, Δ222) (Fig.  10c, d). Together, 
our results suggest that the linker domain enhances the 
antiviral activity of feline A3Z2Z3 but is not essentially 
required for it and that the linker is important for HIV-2/
SIVmac/smm Vif degradation of feline A3Z2Z3. Whether 
the linker domain forms part of the HIV-2/SIV Vif inter-
action surface will be an important future question.
Because the linker insertion is absent in human A3s, 
we tried to learn more about the evolution of this unique 
domain. The DNA sequences in A3Z3 exon 2 encoding 
for the linker region in the double-domain A3Z2Z3 pro-
teins are extremely conserved among members of Feli-
nae and Pantherinae. The linker sequence is indeed more 
conserved than the corresponding Z2 and Z3 domains, 
the evolutionary distances being 0.044  ±  0.006 for the 
Z2 stretch, 0.011 ± 0.006 for the linker and 0.018 ± 0.004 
for the Z3 stretch (overall average pairwise nucleo-
tide distance ±  bootstrap standard error estimate). The 
evolutionary origin of the linker remains neverthe-
less obscure, as systematic BLASTn and BLAT searches 
using this linker sequence as seed did not retrieve hits 
beyond spurious matches. However, tBLASTn success-
fully retrieved hits associated with A3 genes: in the 5′ 
untranslated region of the A3 gene (XR_434780) in the 
Weddell seal genome, in the 5′ untranslated region of the 
A3 gene (FJ716808) in the camel genome, as well as in 
the 5′ regulatory region of the A3 gene (FJ716803) in the 
pig genome. The only very remote hit in primates with 
linker-similar sequence could be located in an A3 gene 
of tarsier (XM_008049574.1), but similarity levels do not 
allow in this case claiming common ancestry.
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HIV‑1 Vif weakly interacts with feline A3Z2Z3
The finding that HIV-2 Vif counteracts one of the feline 
A3s reinforces the view that the initially described spe-
cies-specificity of Vifs [63] is not absolute [36, 52]. For 
the generation of an HIV-1 animal model based on the 
cat, it would of advantage to understand whether feline 
A3 proteins are structurally accessible for HIV-1 Vif. We 
show here that HIV-1 fails to degrade feline A3 proteins 
(Figs.  1b, 10b) and appears only to bind weakly to the 
feline A3Z2Z3 protein compared to FIV Vif (Additional 
file 1: Fig. S10A).
The structural model of feline A3Z2Z3 was used to 
rationalize the binding of HIV-1 Vif to A3Z2Z3. When 
comparing the amino acid sequences of A3G and feline 
A3s, we noticed that the HIV-1 Vif binding domain 
124-YYFWDPDY-131 is conserved in feline A3Z2 (Addi-
tional file 1: Fig. S10B). This domain spans amino acid res-
idues with a well-characterized role in Vif-binding, such 
as 128-DPD-130 [65] and the recently characterized Y125 
[66] in the β4-α4 loop of human A3G [67]. In the feline 
A3Z2 domain we find DPN instead of the DPD motif; 
however, in human A3G DPN binds to HIV-1 Vif as wild-
type DPD [65]. As our structural model of A3Z2Z3 in 
comparison to the soluble N-terminal domain (sNTD) 
of A3G [68] revealed that the two regions around these 
residues are similarly accessible (Fig.  7b), we attempted 
to restore binding of HIV 1 Vif to feline A3Z2Z3 by a 
N133D mutation, resulting in a YYFWDPD133Y motif 
sequentially identical to the one in A3G (Additional file 1: 
Fig. S10b). We did not observe degradation of A3Z2Z3.
Fig. 9 SIVmac and HIV‑2 escape inhibition by FcaA3Z2Z3. a, b 293T cells were transfected with expression plasmids for a SIVmacΔvif‑Luc (SIVmacΔvif) 
or SIVmac‑Luc (SIVmac WT) or b HIV‑2Δvif‑Luc (HIV‑2Δvif ) or HIV‑2Δvif‑Luc + HIV‑2 Vif (HIV‑2 WT), together with expression plasmids for HsaA3G or 
FcaA3s, pcDNA3.1 (+) was used as a control (vector). Reporter virus infectivity was determined by quantification of luciferase activity in 293T cells 
transduced with vector particles after normalizing for reverse transcriptase activity. Luc luciferase. c Lysates of SIVmac producer cells were used to 
detect the expression of FcaA3s and SIVmac capsid by anti‑HA and anti‑p27 antibodies, respectively. SIVmac Vif cannot be detected because of 
the unavailability of a suitable antibody. d Lysates of HIV‑2 producer cells were used to detect the expression of FcaA3s and HIV‑2 Vif by anti‑HA 
and anti‑V5 antibody, respectively. BIR, BOB, SHO and VAN represent FcaA3Z2Z3s including polymorphic sequences of exon 4 of four different Felis 
catus breeding lines: BIR Birman, BOB Japanese Bobtail, SHO British Shorthair, VAN Turkish Van. Asterisks represent statistically significant differences: 
***p < 0.001; **0.001 < p < 0.01; *0.01 < p < 0.05; nsp > 0.05 (Dunnett t test)
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N133D by HIV-1 Vif (Additional file 1: Fig. S10C), how-
ever; neither were mutations of P132 to introduce addi-
tional side chain interactions successful in that respect 
(Additional file  1: Figs. S10B, S10C). As to a possible 
explanation, for A3C, which is structurally highly simi-
lar to the sNTD of A3G [68], another motif of residues 
critical for Vif binding was found, centering on F75, Y86, 
F107, and H111 [69] (Fig. 7c). The sequentially equivalent 
residues of A3Z2Z3 are F78, Y89, F110, and Y114 such 
that the exchange of His versus Tyr may explain the fail-
ing of the binding of HIV-1 Vif. Another possible expla-
nation for A3Z2Z3 is given by the occlusion of space 
required for HIV-1 Vif binding due to the presence of the 
predicted linker domain, where the long unstructured 
regions at the beginning and the end of the structured 
linker part may make it possible that the linker domain 
tips over the Z2 domain, that way shielding the putative 
HIV-1 Vif binding region (Fig. 7a, b).
Discussion
The A3 restriction factors are of extraordinary impor-
tance for the evolution and pathogenicity of lentiviruses 
and likely also of most other retroviruses. Here we identi-
fied A3 residues that are relevant for the FIV Vif inter-
action with both single-domain A3s, A3Z2 and A3Z3 
(results are summarized in Table  1). In addition, we 
analyzed a unique A3 protein insertion domain called 
linker present in the feline A3Z2Z3 protein. The linker 
is suggested to form a homeo-box domain and mediates 
the sensitivity of A3Z2Z3 to degradation by Vifs of the 
HIV-2/SIVmac/smm group of primate lentiviruses.
Our knowledge about the interaction regions of A3s 
and of human and non-human lentivirus Vifs is limited. 
It was discussed that Vif is not simply a linker between 
the substrate A3 and the E3 ubiquitin ligase [70, 71]. In 
our study we investigated the interaction of three groups 














































Fig. 10 The linker region in FcaA3Z2Z3 is important for HIV‑2/SIVmac/smm Vif induced degradation. a Schematic representation of FcaA3Z2Z3 
mutants (ΔLinker, Δ222, Δ210). Z2 and Z3 domains are shown as yellow or blue rectangle, respectively. The linker from amino acid 192–241 is shown 
as white rectangle. b The Vif sensitivity of FcaA3Z2Z3 mutants was analyzed by co‑transfecting expression plasmids of the A3 mutants together 
with lentiviral Vifs (from HIV‑1, FIV, SIVmac, HIV‑2 or SIVsmm) into 293T cells. The expression of FcaA3s and Vifs were confirmed by immunoblots and 
anti‑HA and anti‑V5 antibodies, respectively. Cell lysates were also analyzed for equal amounts of total proteins using anti‑tubulin antibody. c Test 
of antiviral activity of linker mutants against FIVΔvif‑luciferase and d against SIVmacΔvif‑luciferase. Infectivity of virions generated with wild‑type 
and mutated A3 was measured on 293T cells transduced by RT activity normalized particles. CPS counts per second. Asterisks represent statistically 
significant differences: ***p < 0.001; **0.001 < p < 0.01; *0.01 < p < 0.05; nsp > 0.05 (Dunnett t test)
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Previous experimental evidence described residue A65 in 
feline A3Z3 in modulating the sensitivity to FIV Vif [56]. 
We identified here two additional residues (L41, I42) in 
feline A3Z3 whose combined mutation resulted in an A3 
protein that was resistant even to degradation by very 
high amounts of co-expressed FIV Vif. The mutated feline 
A3Z3 protein clearly showed reduced binding to FIV Vif, 
supporting the model that Vif binding to A3 is needed for 
A3 degradation. In feline A3Z2 residues D165 and H166 
were also found to regulate the FIV Vif induced degrada-
tion, but mutations in these positions did not block the 
binding to FIV Vif in co-immunoprecipitation assays. 
This observation demonstrates that Vif binding to A3s is 
not sufficient for A3 degradation. Supporting evidence 
that Vif interaction is necessary but not sufficient is com-
ing from reports describing that HIV-1 NL4-3 Vif binds 
A3C mutants, A3B and A3H without inducing APOBEC3 
degradation [71–73]. The qualitative co-immunoprecipi-
tation assays used in our study did not much differentiate 
the binding strength of individual Vif-A3 pairs, and it is 
very well possible that a weak interaction of e.g. HIV-1 
Vif with feline A3Z2Z3 is below a threshold to form a sta-
ble E3 ligase complex. However, the binding of mutated 
feline A3Z2.DH-YN to FIV Vif appeared to be robust, 
indicating a more complex mechanism. Studies on HIV-1 
Vif binding to human A3B and A3H similarly concluded 
that the interaction strength is not the only determinant 
for complete Vif-mediated degradation, and the indi-
vidual interfaces of the A3-Vif pair additionally regulate 
degradation [72].
Recently, Richards et al. [74] presented a wobble model 
of the evolution of the Vif-A3 interaction. This model 
implicates that Vif forms several interactions, of which 
some are essential and some provide additional stabiliz-
ing contacts. Based on this idea, only if Vif forms a suffi-
cient network of interactions with its A3 binding partner, 
a functional interaction is made. Suboptimal, destabilized 
interactions could be restored by the evolution of com-
pensatory changes in Vif–A3 interface. It is thus possible 
that in feline A3Z3 residue A65 and L41, I42 are major 
independent interactions in the Vif-A3 interface, whereas 
in feline A3Z2 D165 and H166 represent one of the rel-
evant interacting points for FIV Vif complex formation, 
while additional contact points still exist. Such a subop-
timal Vif-A3 interaction might, for example, not be suf-
ficient to facilitate E3 ligase conjugation of K48-linked 
polyubiquitin chains that are generally recognized by the 
proteasome.
The exact Vif-A3 interfaces are not known, because 
high-resolution structures have been only solved of sin-
gle proteins such as of Z1- and Z2-domain human pro-
teins (A3A, A3C), of the N-terminal Z2- and C-Terminal 
Z1-domain of human A3G, of the C-terminal Z2-domain 
of A3F and of HIV-1 Vif [67, 75, 76]. The structures of the 
full-length double domain A3s are unknown, however. 
Human A3Z1s and A3Z2s are globular proteins with six 
α-helices and five β-sheets arranged in a characteristic 
motif (α1-β1-β2/2′-α2-β3-α3-β4-α4-β5-α5-α6) [67, 76]. 
In human A3C, A3D and A3F, the HIV-1 Vif binding site 
is conserved and located in a hydrophobic cavity and on 
the surrounding surface of the α2, α3 and α4 helices [69, 
77, 78]. In human A3G, HIV-1 Vif binds a surface dif-
ferent to the binding region in A3C/D/F, with residues 
Y125, 128-DPN-130 in the β4-α4 loop being important 
for HIV-1 Vif binding [65, 66]. In the human Z3 protein 
A3H, binding of HIV-1 Vif is mediated by residue 121 
Table 1 Summary Vif-mediated A3 degradation
Degradation of A3 by Vif: ++, mostly degraded; ±, partial degradation with high amount of Vif; −, no degradation
Rescue of infection by Vif: ++, complete rescue; ±, partial rescue; −, no rescue
ND not done
a Feline A3: A3s from domestic cat Felis catus
b Experiments to rescue the infection were not done with HIV-1 and SIVsmm
Feline A3a Degradation by Vif Rescue of infection by Vifb
FIV HIV‑1 HIV‑2 SIVmac/smm FIV HIV‑2 SIVmac
A3Z2 ++ − − − ND − −
A3Z2.DH‑YN − ND ND ND ND ND ND
A3Z3 ++ − − − ++ − −
A3Z3.A65I ± ND ND ND ± ND ND
A3Z3.LI‑AA ± ND ND ND ± ND ND
A3Z3.A65I + LI‑AA − ND ND ND − ND ND
A3Z2Z3 ++ − ++ ++ ++ ++ ++
A3Z2Z3‑M − ND ++ ++ − ND ND
A3Z2Z3ΔLinker ++ − ± ± ND ND ND
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(either E or D) [79, 80]. Based on our structural model 
of feline A3Z2Z3 (Fig. 7b), we locate the residues impor-
tant for FIV Vif binding in feline A3Z2Z3 at the domain 
boundary of the Z2 and the Z3 domains, distant to the 
binding motifs in human A3s (Fig. 7c, d).
In feline A3Z2, the presumed HIV-1 Vif-binding 
domain of human A3G, the β4-α4 loop, is conserved. 
Nevertheless, HIV-1 Vif fails to degrade feline A3Z2 or 
A3Z2Z3 despite the presence of the well-characterized 
residues DPN (in A3G residues 128–130) and Y125 [65, 
66]. Based on our structural model, we suggest that the 
β4-α4 loop of feline A3Z2 is surface exposed. This sug-
gests that the Z2-domain of human A3G contains in 
addition to the Y125, 128-DPN-130 motif residues for 
HIV-1 Vif binding that are absent or hidden in feline 
A3Z2 or A3Z2Z3. Indeed, the presences of such impor-
tant residues outside this motif in A3G were recently 
postulated [68, 81]. In addition to FIV Vif, we and others 
found previously that HIV-2/SIVmac/smm Vifs induce 
degradation of feline A3Z2Z3 [46, 51] by possibly tar-
geting the unique linker domain. The previously called 
linker, a domain insertion in feline A3Z2Z3, is not found 
in any double-domain A3 protein of human or mouse 
origin. Our modelling results suggest that the insertion 
forms a homeo-box domain-like structure that protrudes 
the Z2-Z3 structure.
In general, it appears that double-domain A3 proteins 
display stronger antiviral activities than single-domain 
A3s. The evolution of double-domain encoding A3 genes 
could thus have been most likely adaptive, as it signifi-
cantly increased the host fitness against retroviral infec-
tions. Our results suggest that primates and felids could 
have evolved double-domain A3s through different 
routes. The sequence of the linker insertion is located in 
5′UTR of the felid A3Z3 gene in exon 2, which is exclu-
sively translated in read-through transcripts spanning the 
A3Z2 and A3Z3 genes in felines (Fig. 1a). The sequence 
encoding for exon 2 seems to be restricted to members 
of Felinae and Pantherinae. In this sense, the A3Z2Z3 
linker region resembles an orphan domain specific to 
Feliformia, and the linker could thus be a synapomor-
phy of this clade. Nevertheless, homology searches iden-
tified an enrichment of significantly remote tBLASTn 
hits associated with regulatory or non-coding regions 
of A3 genes in the genomes of different species, in the 
carnivore Weddell seal and in the artyodactyls pig and 
camel. This concentration of sequences with a possible 
common origin with the feline A3Z2Z3 linker found in 
the close vicinity of the A3 genes in other species within 
Laurasiatheria suggests that the linker could have been 
recruited as a coding sequence into the feline A3Z2Z3 
mature mRNA from a pre-existent non-coding possibly 
regulatory sequence, in an example of gain of function. 
This sequence could have been recruited after point 
mutation/s resulting in stop codon removal, introduc-
tion of frameshifts or unmasking previously cryptic func-
tional sites [82] during the evolution of carnivores, after 
the split Caniformia/Feliformia but before the split Pan-
therinae/Felinae. In the case of primates and of rodents 
there are no descriptions of read-through transcripts of 
single domain A3s resulting in mRNAs encoding double-
domain A3s. Instead, the human heterologous double 
domain A3s (i.e. A3B and A3G, both being A3Z2Z1) or 
homologous double domain A3s (i.e. A3D and A3F, both 
being A3Z2Z2) could have evolved after the fusion of 
head-to-tail duplicated genes, as the several rounds of 
gene duplication in the evolutionary history of the A3 
locus in primates suggest [3].
During our evolutionary analysis of the A3Z3 genes, 
we found here for the first time duplicated A3Z3 genes. 
A3Z3 duplications were identified in the genomes of 
different carnivores (the giant panda, the polar bear, 
the Weddell seal and the walrus), but were not found in 
dog and ferret and also not in any felid. The most par-
simonious hypothesis would be that a duplication event 
occurred within Caniformia, after the basal split of Cani-
dae. However, given the inferred position of the most 
recent common ancestor of all A3Z3 in carnivores, and 
given the within-clades and between-clades evolutionary 
distances (Additional file 1: Fig. S3), we propose that an 
ancient A3Z3 duplication event may have occurred prior 
to the Caniformia/Feliformia split. One of the in-paralogs 
would have disappeared in the Felidae ancestor, and at 
least in the dog genome, while both copies would have 
been maintained in most lineages within Caniformia (the 
absence in the ferret genome should be confirmed when 
better quality data are available).
Conclusions
Host-virus arms races formed the Vif-A3 interactions. 
Our data support that the evolution of HIV-1, HIV-2 and 
FIV follow intrinsic currently unexplained evolutionary 
pathways adapting to the antiviral A3 repertoire. This 
study also revealed that the A3 gene evolution included 
newly identified duplications (in-paralogs) of A3Z3 genes 
in some caniformia and the inclusion of a homeobox-
domain in the feline A3Z2Z3 protein. This homeobox 
domain insertion may reflect a transitional situation 
(read-through transcription) of the evolutionary devel-
opment of double Z-domain containing A3 proteins. 
Further resolution of the interaction surface of feline 
A3s with Vif proteins will help us to understand the bio-
chemistry of these interactions and may give us tools to 
explore the HIV-1 Vif interaction with human A3s.
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Methods
Cells and transfections
HEK293T (293T, ATCC CRL-3216), HOS (ATCC CRL-
1543) and TZM-bl cells (NIH AIDS Reagent program [83, 
84]) were maintained in Dulbecco’s high-glucose modi-
fied Eagle’s medium (DMEM, Biochrom, Berlin, Ger-
many) supplemented with 10 % fetal bovine serum (FBS), 
2 mM l-glutamine, penicillin (100 U/ml), and streptomy-
cin (100  μg/ml). Stable A3 expressing cells: FcaA3Z2Z3 
wild type and mutant pcDNA-constructs were digested 
by BglII, and then were transfected into HOS.CD4.CCR5 
cells using Lipofectamine LTX (Thermo Fisher Scien-
tific, Schwerte, Germany) according to manufacturer’s 
instruction, cells stably express feline A3s were selected 
by 750 μg/ml G418 (Biochrom, GmbH) in the following 
3  weeks. The A3s degradation experiments were per-
formed in 24-well plates, 1 × 105 293T cells were trans-
fected with 250 ng A3s expression plasmids together with 
250  ng HIV-1, HIV-2, SIVmac and SIVsmm Vif expres-
sion plasmids or 20 ng codon-optimized FIV Vif expres-
sion plasmid, pcDNA3.1 (+) (Life Technologies) was 
used to fill the total plasmid to 500 ng. To produce FIV-
luciferase viruses, 293T cells were co-transfected with 
0.6  μg FIV packaging construct, 0.6  μg FIV-luciferase 
vector, 1 μg A3 expression plasmid, 0.1 μg VSV-G expres-
sion plasmid; in some experiments pcDNA3.1 (+) (Life 
Technologies) was used instead of Vif or A3 expression 
plasmids. For HIV-2 and SIVmac-luciferase transfec-
tions, 1.2 μg HIV-2-Luc and SIVmac-Luc plasmids were 
used instead of FIV plasmids. At 48 h post transfection, 
cells and supernatants were collected.
Vif and A3 plasmids
FIV-34TF10 (codon-optimized), HIV-1, HIV-2, SIVmac 
and SIVsmm Vif genes were inserted into pcWPRE con-
taining a C-terminal V5 tag [36]. HIV-1 Vif represents 
always HIV-1 Vif from clone NL4-3, except specifically 
stated LAI. HIV-1 Vif LAI is a gift from Viviana Simon 
and does not contain a protein tag [54]. pCPRΔenv 
FIV gag-pol plasmid that in addition expresses Vif was 
described previously [57]. FIV-Lion Vif gene (FIVPle sub-
type B, accession number EU117991) was synthesized 
and codon-optimized. FIV-Lion Vif expression plasmid 
was generated by cloning codon-optimized FIV-Lion Vif 
fragment containing a V5 tag into pcWPRE using EcoRI 
and NotI. All A3s are expressed a carboxy-terminal 
hemagglutinin (HA) tag. Domestic cat and big cat (Pan-
therinae) A3s were described previously [36]. Human 
A3C (HsaA3C) and feline A3Z2b (FcaA3Z2b) chime-
ras were made by overlapping extension PCR. HsaA3C/
FcaA3Z2 chimera Z2C1, Z2C4 and Z2C5 contain resi-
dues 1–22, 1–131 and 1–154 of FcaA3Z2, respectively; 
the remaining C-terminal fragments are derived from 
human A3C. The 5′ and 3′ fragments were amplified 
separately by using primer pairs (Additional file 2: Table 
S1); two fragments were then mixed and amplified with 
the two external primers (Additional file 2: Table S1). To 
make HsaA3C/FcaA3Z2 chimera Z2C30, the first frag-
ment was amplified by primers feApo3.fw and hufe3C 
485.rv using chimera Z2C4 as a template, the second 
fragment was amplified by primers hufe3C 485.fw and 
HA-rv using FcaA3Z2 as a template, the two fragments 
were mixed and amplified with the two external primers. 
The FcaA3Z2b mutants were generated by fusion PCR 
using primer pairs described in Additional file  2: Table 
S1. The final products of HsaA3C/FcaA3Z2 chimeras 
and FcaA3Z2 mutants were cloned into pcDNA3.1 (+) 
using HindIII and XhoI restriction sites. The HsaA3H/
FcaA3Z3 chimeras were constructed by the same method 
using primer pairs listed in Additional file 2: Table S2. To 
make FcaA3Z2bZ3-M, the PCR products of FcaA3Z2b 
DH-YN and FcaA3Z3 A65I  +  LI-AA were fused, and 
then inserted into pcDNA3.1 (+) by EcoRI and NotI 
restriction sites. The FcaA3Z2Z3 mutation constructs 
were generated by using the primers shown in Additional 
file 2: Table S3.
Viruses and infection
To produce FIV single-cycle luciferase viruses (FIV-Luc), 
293T cells were co-transfected with the replication defi-
cient packaging construct pFP93, a gift from Eric M. 
Poeschla [85], which only expresses gag, pol, and rev; 
the FIV luciferase vector pLinSin [4]; a VSV-G expres-
sion plasmid pMD.G; FcaA3s expression plasmids; FIV 
Vif expression plasmid; or empty vector pcDNA3.1 (+). 
To produce SIV-Luc viruses, 293T cells were co-trans-
fected with SIVmac-Luc (R-E-); or SIVmac-Luc (R-E-)
Δvif [63]; and FcaA3s expression plasmids. HIV-2-Luc 
was produced by co-transfecting 293T cells with HIV-2 
packaging plasmid pHIV2Δ4 [86]; transfer vector plas-
mid HIV-2-luc (SV40) [64]; pMD.G, together with 
FcaA3s expression plasmids or empty vector pcDNA3.1 
(+) and HIV-2 Vif-V5 expression plasmid or pcDNA3.1 
(+) empty vector. The reverse transcriptase (RT) activity 
of FIV, SIVmac and HIV-2 were quantified by using the 
Cavidi HS lenti RT kit (Cavidi Tech, Uppsala, Sweden). 
For reporter virus infection, 293T cells were seeded in 
96-well plate  1  day before transduction. After normal-
izing for RT activity, the same amounts of viruses were 
used for infection. Three days post transduction, firefly 
luciferase activity was measured with the Steadylite HTS 
reporter gene assay system (Perkin-Elmer, Cologne, Ger-
many) according to the manufacturer’s instructions on a 
MicroLumat Plus luminometer (Berthold Detection Sys-
tems, Pforzheim, Germany). Each sample was performed 
transduction in triplicates; the error bar of each triplicate 
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was shown. Replication-competent HIV-1 plasmids NL-
BaL.vifFIV were described previously [36]. NL-BaL.vifFIV 
virus stocks were prepared by collecting the supernatant 
of transfected 293T cells. The kinetics of viral spread-
ing replication was determined with HOS.CD4.CCR5.
FcaA3s cells by infection with MOI 0.01 of NL-BaL.vifFIV. 
Spreading virus replication was quantified over 15  days 
by infecting 10 μl supernatant to TZM-bl cells. All exper-
iments were repeated independently at least three times.
Immunoblot analysis
Transfected 293T cells were lysed in radioimmunopre-
cipitation assay (RIPA) buffer (25 mM Tris–HCl [pH7.6], 
150  mM NaCl, 1  % NP-40, 1  % sodium deoxycholate, 
0.1  % sodium dodecyl sulfate [SDS], protease inhibitor 
cocktail set III [Calbiochem, Darmstadt, Germany]). The 
expression of FcaA3s and lentivirus Vif were detected by 
mouse anti-hemagglutinin (anti-HA) antibody (1:7500 
dilution, MMS-101P; Covance, Münster, Germany) and 
mouse anti-V5 antibody (1:4500 dilution, MCA1360, 
ABDserotec, Düsseldorf, Germany) separately, the tubu-
lin and SIV capsid protein were detected using mouse 
anti-α-tubulin antibody (1:4000, dilution, clone B5-1-2; 
Sigma-Aldrich, Taufkirchen, Germany), HIV Vif LAI was 
detected by HIV-1 Vif monoclonal antibody (#319) (NIH 
AIDS Reagent Program [87]) and mouse anti-capsid p24/
p27 MAb AG3.0 (1:50 dilution [88]) separately, followed 
by horseradish peroxidase-conjugated rabbit anti-mouse 
antibody (α-mouse-IgG-HRP; GE Healthcare, Munich, 
Germany), and developed with ECL chemiluminescence 
reagents (GE Healthcare). Encapsidation of FcaA3 pro-
teins into FIV particles: HEK293T cells were transfected 
with 600 ng pFP93, 600 ng of pLinSin, 100 ng pMD.G and 
1000  ng of FcaA3 constructs. Viral supernatants were 
collected 48 h later, overlaid on 20 % sucrose and centri-
fuged for 4 h at 14,800 rpm in a table top centrifuge. Viral 
pellet was resuspended in RIPA buffer, boiled at 95  °C 
for 5  min with Roti load reducing loading buffer (Carl 
Roth, Karlsruhe, Germany) and resolved on a SDS-PAGE 
gel. The FcaA3s and tubulin proteins were detected as 
the above method. VSV-G and FIV p24 proteins were 
detected using mouse anti-VSV-G antibody (1:10,000 
dilution; clone P5D4; Sigma-Aldrich) and mouse anti-
FIV p24 antibody (1:2000 dilution; clone PAK3-2C1; NIH 
AIDS REPOSITORY) separately, followed by horserad-
ish peroxidase-conjugated rabbit anti-mouse antibody 
(α-mouse-IgG-HRP; GE Healthcare, Munich, Germany), 
and developed with ECL chemiluminescence reagents 
(GE Healthcare).
Immunofluorescence and flow cytometry
HOS cells grown on polystyrene coverslips (Thermo 
Fisher Scientific, Langenselbold, Germany) were 
transfected with expression plasmids for FcaA3 wild-type 
and mutants or together with FIV Vif-TLQAAA using 
Lipofectamine LTX (Life Technologies). At day one post 
transfection, cells were fixed in 4 % paraformaldehyde in 
PBS for 30 min, permeabilized in 0.1 % Triton X-100 in 
PBS for 15 min, incubated in blocking buffer (FBS in PBS) 
for 1  h, and then cells were stained by mouse anti-HA 
antibody in a 1:1000 dilution in blocking solution for 1 h. 
Donkey anti-mouse Alexa Fluor 488 (Life Technologies) 
was used as a secondary antibody in a 1:300 dilution in 
blocking solution for 1 h. FIV Vif-TLQAAA was stained 
by rabbit anti-V5 antibody in a 1:1000 dilution in block-
ing solution for 1 h. Donkey anti-rabbit Alexa Fluor 594 
(Life Technologies) was used as a secondary antibody in 
a 1:300 dilution in blocking solution for 1 h. Finally, DAPI 
was used to stain nuclei for 2 min. The images were cap-
tured by using a 40× objective on a Zeiss LSM 510 Meta 
laser scanning confocal microscope (Carl Zeiss, Cologne, 
Germany). To analyze CD4 and CCR5 expression level of 
HOS.CD4.CCR5.FcaA3s, cells were stained by α-hCD4 
PE mouse IgG1k (Dako, Hamburg, Germany) and 
α-hCCR5 FITC (BD Bioscience, Heidelberg, Germany) 
separately according to the manufacturer’s instruction. 
The measurement was carried out by BD FACSanto (BD 
Bioscience). Data analysis was done with the Software 
FlowJo version 7.6 (FlowJo, Ashland, USA).
Immunoprecipitation
To determine Vif and A3 binding, 293T cells were co-
transfected with 1  μg FIV Vif TLQAAA-V5 and 1  μg 
FcaA3 wild-type or mutants or pcDNA3.1 (+). 48 h later, 
the cells were lysed in IP-lysis buffer (50  mM Tris/HCl 
pH 8, 1 mM PMSF, 10 % Glycerol, 0.8 % NP-40, 150 mM 
NaCl, and protease inhibitor cocktail set III (Calbio-
chem, Darmstadt, Germany). The lysates were cleared 
by centrifugation. The supernatant were incubated with 
20 μl α-HA Affinity Matrix Beads (Roche) at 4 °C for 2 h. 
The samples were washed 5 times with lysate buffer on 
ice. Bound proteins were eluted by boiling the beads for 
5 min at 95 °C in SDS loading buffer. Immunoblot analy-
sis and detection were done as described.
3D‑PCR
293T cells (5 × 105 cells/well in a 6-well plate) were trans-
fected with 600 ng pFP93, 600 ng pLinSin, 100 ng pMD.G 
and 1000  ng FcaA3s expression plasmids or pcDNA3.1 
(+) as a control. 48 h later, the viral supernatant was har-
vested, filtered (0.45 µm) and treated with DNase I (Life 
Technologies) at 37 °C for 1 h. 200 μl of supernatant was 
used for infecting 293T cells. 12  h post transduction, 
293T cells were washed with PBS and DNA was isolated 
using DNeasy blood and tissue kit (Qiagen, Hilden, Ger-
many). A 714-bp fragment of within the spliced luciferase 
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gene was amplified using the primers 5′-GATATGTG-
GATTTCGAGTCGTC-3′ and 5′-GTCATCGTCTTTC-
CGTGCTC-3′. For selective amplification of the 
hypermutated products, the PCR denaturation temper-
ature were lowered stepwise from 87.6 to 83.5  °C (83.5, 
84.2, 85.2, 86.3, 87.6  °C) using a gradient thermocycler. 
The PCR parameters were as follows: (1) 95 °C for 5 min; 
(2) 40 cycles, with 1 cycle consisting of 83.5–87.6 °C for 
30 s, 55 °C for 30 s, 72 °C for 1 min; (3) 10 min at 72 °C. 
PCRs were performed with recombination Taq DNA pol-
ymerase (Thermo Fisher Scientific).
Purification of GST tagged proteins and pull down assay
Feline A3Z2 and A3Z3 coding sequences were cloned in 
pGEX-6P2 vector (GE healthcare) with a C terminal HA 
tag to produce fusion proteins GST-FcaA3Z2-HA and 
GST-FcaA3Z3-HA (PCR primer in Additional file 2: Table 
S4). GST alone and fusion proteins were overexpressed in 
E. coli Rosetta (DE3) cells (EMD Millipore, Darmstadt, 
Germany) and purified by affinity chromatography using 
Glutathione Sepharose 4B beads (GE healthcare). After 
the culture of transformants until 0.6 OD600, cells were 
induced with 1  mM isopropyl-beta-d-thiogalactopyra-
noside (IPTG) and 1  µM ZnSO4 and cultured at 18  °C 
overnight. GST and Feline A3Z2/Z3 harboring cells were 
washed with PBS and lysed with 1× Bug buster protein 
extraction reagent (EMD Millipore) containing 50  mM 
Tris (pH 7.0), 10  % glycerol, and 1  M NaCl clarified by 
centrifugation and the soluble protein fraction was mixed 
with pre-equilibrated glutathione Sepharose beads. After 
3 h incubation at 4 °C in end-over-end rotation, the beads 
were washed thrice with wash buffer containing 50 mM 
Tris (pH 8.0), 10 % glycerol and 500 mM NaCl and a sin-
gle wash with the mild lysis buffer (50 mM Tris (pH 8), 
1 mM PMSF, 10 % glycerol, 0.8 % NP-40, 150 mM NaCl 
and 1× complete protease inhibitor). These GST pro-
tein bound beads are used for the subsequent binding 
assay. GST pull down assay to detect direct binding with 
Vif of FIV: The protocol of protein–protein interactions 
was adapted from a previously described procedure [89]. 
HEK293T cells were transfected with 1.5 µg of FIV Vif-
V5 coding plasmid and incubated for 48 h. Soluble pro-
tein fraction of HEK293T cells were obtained by lysing 
the cells with mild lysis buffer (50 mM Tris (pH 8), 1 mM 
PMSF, 10 % glycerol, 0.8 % NP-40, 150 mM NaCl, and 1× 
complete protease inhibitor (Calbiochem) and a 30 min 
centrifugation at 14,800 rpm. A fraction of the superna-
tant was kept for immunoblots; remaining lysates were 
equally added on the bead samples GST, GST-FcaA3Z2-
HA and GST-FcaA3Z3-HA and incubated overnight at 
4  °C in end-over-end rotation. Next day, the beads were 
washed thrice with the mild lysis buffer and the GST pro-
tein and protein complexes were eluted by adding wash 
buffer containing 25  mM reduced glutathione. A frac-
tion of the eluted proteins (equal amount) were boiled 
at 95 °C for 5 min with Roti load reducing loading buffer 
(Carl Roth) and resolved on a SDS-PAGE gel. FIV Vif and 
GST-FcaA3s were detected by anti-V5 and -HA antibody, 
respectively. Coomassie brilliant blue stained gel was 
also added to show the purity of GST and FcaA3 fusion 
proteins.
Evolutionary analyses
The initial set of A3 sequences was taken from Münk 
and coworkers [3]. These sequences were used as seeds 
for BLASTn, tBLASTn and BLAT searches to recover 
additional A3 sequences from genomes in Carnivora. 
The final dataset (closed on November 2015) contained 
four A3Z1 sequences from four Caniformia species, six 
A3Z2 sequences from six Caniformia species, eleven 
A3Z2 sequences from six Feliformia species, ten A3Z3 
sequences from five Caniformia species and five A3Z3 
sequences from five Feliformia species. Sequences were 
aligned at the amino acid level with MUSCLE [90]. The 
final alignment encompassed 629 and 269 alignment pat-
terns at the nucleotide level and at the amino acid level, 
respectively. Phylogenetic inference was performed with 
RAxML_v8.2 [91, 92] using the GTR + 4Γ model at the 
nucleotide level and LG  +  Γ model at the amino acid 
level, the model choice done after initial maximum like-
lihood searches with RAxML. Additional phylogenetic 
inference was performed separately for the A3Z2 and 
A3Z3 genes using the same settings. In all cases, no sig-
nificant differences between amino acid and nucleotide 
tree topologies were observed using the Shimodaira–
Hasegawa test [93]. Phylogenetic supernetworks were 
constructed with SplitsTree_v4 [94] using 1000 either 
nucleotide or amino acid bootstrapped maximum likeli-
hood trees. Selection on individual codons was inferred 
under a Bayesian framework with SELECTON V2.4 
(http://selecton.tau.ac.il/) [95] contrasting the M8 and 
M8a models, and with DATAMONKEY (http://www.
datamonkey.org/) using the Random Effects Likelihood 
(REL) model [96].
Statistical analysis
Data are represented as the mean with SD in all bar dia-
grams. Statistically significant differences between two 
groups were analyzed using the unpaired Student’s t test 
with GraphPad Prism version 5 (GraphPad software, San 
Diego, CA, USA). Validity of the null hypothesis was ver-
ified with significance level at α value = 0.05.
Homology modelling of feline A3Z2Z3 protein
The homology modeling of the linker region of the 
feline A3Z2Z3 was performed in several steps: First, the 
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in-house meta-tool TopModel [59, 60] was used to com-
pute a consensus alignment for the feline A3 sequences 
to the structural model of the human A3G [58] using 13 
different alignment programs (Additional file  2: Table 
S5). From the consensus alignment, the feline A3 linker 
was identified and then submitted to TopModel for 
automated structure prediction using eight state-of-the-
art threading programs (Additional file 2: Table S5). The 
identified templates (2YS9, chain A (19.4  %); 2MMB, 
chain A (17.1 %); 2DA4, chain A (14.7 %); 2LFB, chain 
A (9.2  %) and 1FTZ, chain A (12.9  %); sequence iden-
tities with respect to the linker are given in parenthe-
ses) were aligned to the linker sequence with TopModel 
using threading, sequence, and structural alignment 
programs, to produce a large alignment ensemble from 
every combination of the top three ranked templates 
and the target sequence. These alignments were mod-
eled using Modeller9.1 [97], refined with RASP [98], and 
ranked using the in-house meta-tool for model quality 
assessment TopScore (D. Mulnaes, H. Gohlke, unpub-
lished results), which combines quality assessments 
from eight different model quality assessment programs 
(Additional file 2: Table S5). The top ranked models for 
each template combination were refined with ModRe-
finer [99] and used as templates for a second round of 
modeling where bad scoring regions were removed. 
The resulting models were re-ranked and refined, and 
the top ranking model was selected as the linker rep-
resentative. The model of the rest of the feline A3Z2Z3 
was made with TopModel in a similar fashion using the 
feline–human consensus alignment. The linker domain 
was manually positioned near the linker region gap, 
unstructured parts were connected to the rest of the 
feline A3Z2Z3 and minimized using the MAB force 
field [100] as implemented in Moloc, thereby keeping all 
other protein atoms fixed.
Homology modelling of human A3H and feline A3Z2b 
and A3Z3 proteins
The models of the three proteins were built using the 
default settings in TopModel and all possible combina-
tions of the top three ranked templates in each case. 
For the human A3H model, the templates were: PDB 
ID 4  J4  J, chain A, 35  % identity/96  % coverage; 2KBO, 
chain A, 37/95  %; 2RPZ, chain A, 30/94  %, resulting in 
a model with 84 % accuracy according to TopScore. For 
the feline A3Z2b model, the templates were: 3VM8, 
chain A, 42/94 %; 2KBO, chain A, 39/94 %; 1M65, chain 
A, 10/87  %, resulting in a model with 88  % accuracy 
according to TopScore. For the feline A3Z3 model, the 
templates were: 4J4J, chain A, 31/91 %; 2KBO, chain A, 
36/90  %; 2RPZ, chain A, 24/92  %, resulting in a model 
with 84 % accuracy according to TopScore.
Additional files
Additional file 1: Figure S1. Cellular localization of feline A3s and FIV 
Vif. HOS cells were transfected with FcaA3Z2b, FcaA3Z3, or FcaA3Z2Z3 
(all with HA‑tag), together with FIV Vif‑TLQAAA. To detect A3 (green) 
immunofluorescence, staining was performed with an anti‑HA antibody. 
To detect FIV Vif (red) immunofluorescence, staining was performed with 
an anti‑V5 antibody. Nuclei (blue) were visualized by DAPI staining. Figure 
S2. Comparison of protein sequences of A3s and Vif. (A, B) The sequence 
alignment of (A) FcaA3Z2 (FcaA3Z2b), (B) FcaA3Z3 and big cat A3 proteins. 
The D165‑H166 and L40‑I41 + A65 domains that are essential for FIV Vif 
induced degradation are marked by red boxes. (C) Sequence alignment of 
domestic cat FIV Vif (FIVfca subtype 34TF10) and lion FIV (FIVple subtype E) 
Vif. The C187 and C190 that are essential for induced FcaA3s degradation 
and marked the presumed BC box (TLQ/SLQ) marked by red boxes. (D) 
Sequence alignment of HIV‑1 (strain NL4‑3) and HIV‑2 (strain RodA) Vif. The 
CUL5 box (HCCH) and BC box (SLQ) were marked by red boxes. Pti, Ple, Lly 
and Pco represent Panthera tigris corbetti; Panthera leo bleyenberghi; Lynx 
lynx; Puma concolor. Figure S3. Evolutionary supernetwork of A3 sequences 
retrieved from carnivores. The network was constructed with SplitsTree_v4 
using 1,000 maximum likelihood bootstrapped trees created with 
RAxML_v8.2. Scale bar is given in substitutions per site. The approximate 
position of the root obtained using maximum likelihood inference with 
all A3Z1, A3Z2 and A3Z3 sequences from carnivores is indicated in grey. 
(A) The evolutionary distances among A3Z3 sequences within the two 
in‑paralogs within Caniformia (upper branches and left branch) and 
within Feliformia (right branches) are indicated as overall average pairwise 
nucleotide distance ± bootstrap standard error estimate. For each tip, the 
actual sequence orthologous to positions 38‑44 in the F. catus A3Z3 gene 
are given in parentheses. The inset displays the evolutionary relation‑
ships among the Carnivora species for which we have identified A3Z3 
paralogs. (B) The evolutionary distances among A3Z2 sequences within 
Caniformia (upper branches) and within Feliformia (lower branches) are 
indicated as overall average pairwise nucleotide distance ± bootstrap 
standard error estimate. For each tip, the actual sequence orthologous 
to positions 165‑170 in the F. catus A3Z2 genes are given in parentheses. 
Figure S4. The mutations in FcaA3 that cause resistance to FIV Vif do not alter 
the cellular distribution of FcaA3s. HOS cells were transfected with FcaA3Z2 
(FcaA3Z2b), FcaA3Z2.DH‑YN, FcaA3Z3, FcaA3Z3.A65I + LI‑AA, FcaA3Z2Z3 
or FcaA3Z2Z3‑M (all with HA‑tag). To detect A3 (green) immunofluores‑
cence, staining was performed with an anti‑HA antibody. Nuclei (blue) 
were visualized by DAPI staining. Figure S5. Sequence alignment of feline 
APOBEC3. Sequence alignment of feline A3Z2Z3 and human A3G as gen‑
erated by the TopModel approach. The Z2 and Z3 domains are underlined 
in yellow and blue, respectively. The sequence of the linker domain is 
underlined in magenta. Helical regions and β‑strands are depicted as red 
helices and green arrows, respectively. In addition, the alignments of three 
template structures used to model the structure of the linker domain 
are given (PDB IDs 2YS9, 2DA4, 2MMB). Figure S6. Expression of CD4 and 
CCR5 receptors on the surface of HOS (red) and HOS.CD4.CCR5 cells (blue) 
expressing feline A3Z2Z3 or A3Z2Z3‑M. CD4 and CCR5 were detected by 
flow cytometry and anti‑CD4 and anti‑CCR5 antibodies. Numbers indicate 
the percentage of positive cells. HOS cells served as background control. 
Figure S7. The mutated FcaA3s are encapsidated and inhibit FIV by cytidine 
deamination. (A) The mutated FcaA3s can inhibit the infectivity of FIVΔvif 
reporter viruses. 293T cells were co‑transfected with plasmids for FIVΔvif 
luciferase together with FcaA3s. 48 h later, supernatant normalized for 
reverse transcriptase activity was used to transduce 293T cells. Luciferase 
activity was determined two days post transduction. Asterisks represent 
statistically significant differences: ***, p < 0.001; **, 0.001 < p < 0.01; 
*, 0.01 < p < 0.05; ns, p > 0.05 [Dunnett t test]. (B) Immunoblot of FIV 
producer cells and VLPs used for (A). Encapsidation of wild‑type and 
mutated feline A3s into FIVΔvif virus like particles (VLPs), A3 proteins were 
detected by anti‑HA antibody. Tubulin detection for equal loading of cell 
lysate was done using anti‑tubulin, for demonstration of equal loading 
of FIV VLPs VSV‑G and FIV p24 proteins were detected by anti‑VSV‑G 
and anti‑FIV p24 antibodies separately. (C) Encapsidated wild‑type and 
mutated FcaA3s deaminate cytidines FIV genomes. FIVΔvif was produced 
in the absence and presence of wild‑type and mutant FcaA3s (FcaA3Z3, 
Page 21 of 23Zhang et al. Retrovirology  (2016) 13:46 
Abbreviations
FIV: feline immunodeficiency virus; HIV: human immunodeficiency virus; SIV: 
simian immunodeficiency virus; APOBEC3: apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide‑like; Vif: viral infectivity factor; UTR: untranslated 
region.
Authors’ contributions
ZZ, QG, AAJV, AH, BPK, and SH conducted experiments. DM, SHJS and HG 
generated the feline A3 homology model. IGB analyzed the evolutionary 
origin of feline A3s. KS, KC, DH, SHJS, HG and CM analyzed data and conceived 
experiments. IGB, SHJS, HG and CM wrote the manuscript. CM conceived the 
study. All authors read and approved the final manuscript.
Author details
1 Clinic for Gastroenterology, Hepatology, and Infectiology, Medical Faculty, 
Heinrich‑Heine‑University Düsseldorf, Building 23.12.U1.82, Moorenstr. 5, 
40225 Düsseldorf, Germany. 2 Department of Medical Biotechnology, Paul‑
Ehrlich‑Institute, Paul‑Ehrlich‑Str. 51‑59, 63225 Langen, Germany. 3 Institute 
of Biochemistry, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 
40225 Düsseldorf, Germany. 4 Institute of Pharmaceutical and Medicinal 
Chemistry, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düs‑
seldorf, Germany. 5 Laboratory of Viral Pathogenesis, Institute for Virus 
Research, Kyoto University, Kyoto 6068507, Japan. 6 CREST, Japan Science 
and Technology Agency, Saitama 3220012, Japan. 7 MIVEGEC (UMR CNRS 
5290, IRD 224, UM), National Center of Scientific Research (CNRS), 34394 Mont‑
pellier, France. 8 Present Address: BioNTech RNA Pharmaceuticals GmbH, An 
der Goldgrube 12, 55131 Mainz, Germany. 
Acknowledgements
We thank Wioletta Hörschken for excellent technical assistance, Rebecca 
Clemens for discussion and sharing of preliminary data, Yannick Bulliard and 
Didier Trono for the model of the full‑length A3G. We thank Nathanial R. Lan‑
dau, Garry Nolan, Eric Poeschla, and Viviana Simon for reagents. The following 
reagents were obtained through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH: Monoclonal antibody to HIV‑1 p24 (AG3.0) from Jonathan 
Allan, TZM‑bl cells from John C. Kappes, Xiaoyun Wu and Tranzyme Inc., HIV‑1 
Vif monoclonal antibody (#319)) from Michael H. Malim and anti‑FIV p24 
monoclonal (PAK3‑2C1).
Competing interests
The authors declare that they have no competing interests.
Funding
ZZ and QG are supported by a scholarship from China Scholarship Council; 
CM is supported by the Heinz Ansmann foundation.
Received: 8 March 2016   Accepted: 9 June 2016
References
 1. LaRue RS, Jonsson SR, Silverstein KA, Lajoie M, Bertrand D, El‑Mabrouk 
N, Hotzel I, Andresdottir V, Smith TP, Harris RS. The artiodactyl APOBEC3 
innate immune repertoire shows evidence for a multi‑functional 
domain organization that existed in the ancestor of placental mam‑
mals. BMC Mol Biol. 2008;9:104.
 2. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman 
M, Greene WC, Jonsson SR, Landau NR, Löchelt M, et al. Guide‑
lines for naming nonprimate APOBEC3 genes and proteins. J Virol. 
2009;83(2):494–7.
 3. Münk C, Willemsen A, Bravo IG. An ancient history of gene duplications, 
fusions and losses in the evolution of APOBEC3 mutators in mammals. 
BMC Evol Biol. 2012;12:71.
 4. Münk C, Beck T, Zielonka J, Hotz‑Wagenblatt A, Chareza S, Battenberg 
M, Thielebein J, Cichutek K, Bravo IG, O’Brien SJ, et al. Functions, struc‑
ture, and read‑through alternative splicing of feline APOBEC3 genes. 
Genome Biol. 2008;9(3):R48.
 5. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navarat‑
nam N. An anthropoid‑specific locus of orphan C to U RNA‑editing 
enzymes on chromosome 22. Genomics. 2002;79(3):285–96.
 6. Willems L, Gillet NA. APOBEC3 interference during replication of viral 
genomes. Viruses. 2015;7(6):2999–3018.
 7. Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 
2015;479–480:131–45.
 8. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene 
that inhibits HIV‑1 infection and is suppressed by the viral Vif protein. 
Nature. 2002;418(6898):646–50.
 9. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. Resistance of human 
T cell leukemia virus type 1 to APOBEC3G restriction is mediated by 
elements in nucleocapsid. Proc Natl Acad Sci USA. 2007;104(8):2915–20.
 10. Löchelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, 
Truyen U, Rosler U, Battenberg M, Saib A, et al. The antiretroviral activity 
of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc 
Natl Acad Sci USA. 2005;102(22):7982–7.
 11. Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, Rein AR, Fan H, Ross SR. 
Murine leukemia virus glycosylated Gag blocks apolipoprotein B edit‑
ing complex 3 and cytosolic sensor access to the reverse transcription 
complex. Proc Natl Acad Sci USA. 2013;110(22):9078–83.
 12. Rosales Gerpe MC, Renner TM, Belanger K, Lam C, Aydin H, Langlois MA. 
N‑linked glycosylation protects gammaretroviruses against deamina‑
tion by APOBEC3 proteins. J Virol. 2015;89(4):2342–57.
 13. Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, 
Portis JL, Hasenkrug KJ, Evans LH. The glycosylated Gag protein of a 
murine leukemia virus inhibits the antiretroviral function of APOBEC3. J 
Virol. 2010;84(20):10933–6.
 14. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit 
the accumulation of HIV‑1 reverse transcription products in the 
absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem. 
2007;282(4):2587–95.
 15. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronen‑
born AM, Rouzina I, Williams MC, Musier‑Forsyth K, Levin JG. 
FcaA3Z3.A65I + LI‑AA, FcaA3Z2Z3, FcaA3Z2Z3‑M) or HsaA3G. The vector 
particles were used to infect 293T cells. 12 h later, the total cellular DNA 
was extracted and differential DNA denaturation PCR (3D‑PCR) was per‑
formed. Td: denaturing temperature. Figure S8. Vif titration on FcaA3 linker 
mutants. Co‑transfection of increasing amounts of expression plasmids 
for (A) HIV‑2 Vif and (B) SIVmac Vif with constant amounts of the indicated 
A3 expression plasmids. The expression of FcaA3s and Vifs were analyzed 
by anti‑HA and anti‑V5 antibodies, respectively. Cell lysates were also 
analyzed for equal amounts of total proteins using anti‑tubulin antibody. 
Figure S9. Expression and encapsidation of feline A3 linker mutants using (A) 
FIVΔvif and (B) SIVmacΔvif. Immunoblots of corresponding experiments 
shown in Fig. 10C and 10D. Immunoblots of lysates of virus producer cells 
(cell) and virus particles (VLP). A3s were detected by anti‑HA antibod‑
ies, cell lysates were also analyzed for equal amounts of total proteins 
using anti‑tubulin antibody and VLP lysates using anti‑VSV‑G antibody. 
Figure S10. HIV‑1 Vif cannot target the “YYFWDPN/DY” domain in FcaA3. 
(A) CO‑IP of feline A3Z2Z3 (HA tag) with either HIV‑1 Vif (V5 tag) or FIV Vif 
(TLQAAA mutant, V5 tag). A3Z2Z3 immune precipitated and detected by 
anti‑HA antibody, co‑precipitated Vif was detected by anti‑V5 antibody. (B) 
Comparison of the “YYFWDPN/DY” domain in HsaA3G and FcaA3Z2Z3 and 
derived mutations generated in FcaA3Z2Z3, the mutated residues shown 
in bold. (C) FcaA3Z2Z3 mutants were investigated for being sensitive 
for degradation by HIV‑1 Vif. Expression plasmids of FcaA3Z2Z3 mutants 
of HsaA3G were co‑transfected together with HIV‑1 Vif into 293T cells. 
48 h later, Cell lysates were used to detect the expression of FcaA3Z2Z3 
and HIV‑1 Vif by anti‑HA and anti‑V5 antibodies, respectively. Cell lysates 
were also analyzed for equal amounts of total proteins using anti‑tubulin 
antibody.
Additional file 2: Table S1. Primer list used for HsaA3C/FcaA3Z2 chime‑
ras and FcaA3Z2 mutants. Table S2. Primer list used for HsaA3H/FcaA3Z3 
chimeras and FcaA3Z3 mutants. Table S3. Primer list used for FcaA3Z2Z3 
mutants. Table S4. Primer used to clone GST fusion constructs. Table 
S5. The software used in TopModel for threading, alignment and model 
quality estimationa.
Page 22 of 23Zhang et al. Retrovirology  (2016) 13:46 
Deaminase‑independent inhibition of HIV‑1 reverse transcription by 
APOBEC3G. Nucleic Acids Res. 2007;35(21):7096–108.
 16. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, Malim MH. Suppres‑
sion of HIV‑1 infection by APOBEC3 proteins in primary human CD4(+) 
T cells is associated with inhibition of processive reverse transcription as 
well as excessive cytidine deamination. J Virol. 2013;87(3):1508–17.
 17. Wang X, Ao Z, Chen L, Kobinger G, Peng J, Yao X. The cellular antiviral 
protein APOBEC3G interacts with HIV‑1 reverse transcriptase and inhib‑
its its function during viral replication. J Virol. 2012;86(7):3777–86.
 18. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, 
Brown WL, Mansky LM, Gorelick RJ, Harris RS, et al. Human immunode‑
ficiency virus type 1 cDNAs produced in the presence of APOBEC3G 
exhibit defects in plus‑strand DNA transfer and integration. J Virol. 
2007;81(13):7099–110.
 19. Mbisa JL, Bu W, Pathak VK. APOBEC3F and APOBEC3G inhibit HIV‑1 DNA 
integration by different mechanisms. J Virol. 2010;84(10):5250–9.
 20. Kenyon JC, Lever AM. The molecular biology of feline immunodefi‑
ciency virus (FIV). Viruses. 2011;3(11):2192–213.
 21. Pecon‑Slattery J, Troyer JL, Johnson WE, O’Brien SJ. Evolution of feline 
immunodeficiency virus in Felidae: implications for human health and 
wildlife ecology. Vet Immunol Immunopathol. 2008;123(1–2):32–44.
 22. Willett BJ, Hosie MJ. Feline leukaemia virus: half a century since its 
discovery. Vet J. 2013;195(1):16–23.
 23. Rethwilm A, Bodem J. Evolution of foamy viruses: the most ancient of 
all retroviruses. Viruses. 2013;5(10):2349–74.
 24. Hartmann K. Clinical aspects of feline immunodeficiency and 
feline leukemia virus infection. Vet immunol immunopathol. 
2011;143(3–4):190–201.
 25. de Rozieres S, Mathiason CK, Rolston MR, Chatterji U, Hoover EA, Elder 
JH. Characterization of a highly pathogenic molecular clone of feline 
immunodeficiency virus clade C. J Virol. 2004;78(17):8971–82.
 26. Diehl LJ, Mathiason‑Dubard CK, O’Neil LL, Obert LA, Hoover EA. Induc‑
tion of accelerated feline immunodeficiency virus disease by acute‑
phase virus passage. J Virol. 1995;69(10):6149–57.
 27. Obert LA, Hoover EA. Feline immunodeficiency virus clade C 
mucosal transmission and disease courses. AIDS Res Hum Retrovir. 
2000;16(7):677–88.
 28. Lehman TL, O’Halloran KP, Hoover EA, Avery PR. Utilizing the FIV model 
to understand dendritic cell dysfunction and the potential role of den‑
dritic cell immunization in HIV infection. Vet Immunol Immunopathol. 
2010;134(1–2):75–81.
 29. Yamamoto JK, Sanou MP, Abbott JR, Coleman JK. Feline immunode‑
ficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res. 
2010;8(1):14–25.
 30. Elder JH, Lin YC, Fink E, Grant CK. Feline immunodeficiency virus (FIV) 
as a model for study of lentivirus infections: parallels with HIV. Curr HIV 
Res. 2010;8(1):73–80.
 31. O’Brien SJ, Troyer JL, Brown MA, Johnson WE, Antunes A, Roelke ME, 
Pecon‑Slattery J. Emerging viruses in the Felidae: shifting paradigms. 
Viruses. 2012;4(2):236–57.
 32. German AC, Harbour DA, Helps CR, Gruffydd‑Jones TJ. Is feline 
foamy virus really apathogenic? Vet Immunol Immunopathol. 
2008;123(1–2):114–8.
 33. Winkler IG, Lochelt M, Flower RL. Epidemiology of feline foamy 
virus and feline immunodeficiency virus infections in domes‑
tic and feral cats: a seroepidemiological study. J Clin Microbiol. 
1999;37(9):2848–51.
 34. Phung HT, Ikeda Y, Miyazawa T, Nakamura K, Mochizuki M, Izumiya 
Y, Sato E, Nishimura Y, Tohya Y, Takahashi E, et al. Genetic analyses of 
feline foamy virus isolates from domestic and wild feline species in 
geographically distinct areas. Virus Res. 2001;76(2):171–81.
 35. Zielonka J, Münk C. Cellular restriction factors of feline immunodefi‑
ciency virus. Viruses. 2011;3(10):1986–2005.
 36. Zielonka J, Marino D, Hofmann H, Yuhki N, Löchelt M, Münk C. 
Vif of feline immunodeficiency virus from domestic cats pro‑
tects against APOBEC3 restriction factors from many felids. J Virol. 
2010;84(14):7312–24.
 37. Wang J, Zhang W, Lv M, Zuo T, Kong W, Yu X. Identification of a 
Cullin5‑ElonginB‑ElonginC E3 complex in degradation of feline 
immunodeficiency virus Vif‑mediated feline APOBEC3 proteins. J Virol. 
2011;85(23):12482–91.
 38. Chareza S, Slavkovic LD, Liu Y, Rathe AM, Münk C, Zabogli E, Pistello M, 
Löchelt M. Molecular and functional interactions of cat APOBEC3 and 
feline foamy and immunodeficiency virus proteins: different ways to 
counteract host‑encoded restriction. Virology. 2012;424(2):138–46.
 39. Münk C, Hechler T, Chareza S, Löchelt M. Restriction of feline retrovi‑
ruses: lessons from cat APOBEC3 cytidine deaminases and TRIM5alpha 
proteins. Vet Immunol Immunopathol. 2010;134(1–2):14–24.
 40. de Castro FL, Junqueira DM, de Medeiros RM, da Silva TR, Costenaro 
JG, Knak MB, de Matos Almeida SE, Campos FS, Roehe PM, Franco AC. 
Analysis of single‑nucleotide polymorphisms in the APOBEC3H gene of 
domestic cats (Felis catus) and their association with the susceptibility 
to feline immunodeficiency virus and feline leukemia virus infections. 
Infect Genet Evol. 2014;27:389–94.
 41. Mehle A, Goncalves J, Santa‑Marta M, McPike M, Gabuzda D. Phos‑
phorylation of a novel SOCS‑box regulates assembly of the HIV‑1 
Vif‑Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 
2004;18(23):2861–6.
 42. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV‑1 Vif‑Cul5‑
ElonginB‑ElonginC E3 ubiquitin ligase complex through a novel SOCS 
box and upstream cysteines. Genes Dev. 2004;18(23):2867–72.
 43. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G 
ubiquitination and degradation by an HIV‑1 Vif‑Cul5‑SCF complex. Sci‑
ence. 2003;302(5647):1056–60.
 44. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, 
Anderson BD, Yen L, Stanley D, et al. Vif hijacks CBF‑beta to degrade 
APOBEC3G and promote HIV‑1 infection. Nature. 2012;481(7381):371–5.
 45. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T‑cell differentiation factor CBF‑
beta regulates HIV‑1 Vif‑mediated evasion of host restriction. Nature. 
2012;481(7381):376–9.
 46. Yoshikawa R, Takeuchi JS, Yamada E, Nakano Y, Ren F, Tanaka H, Munk C, 
Harris RS, Miyazawa T, Koyanagi Y, et al. Vif determines the requirement 
for CBF‑beta in APOBEC3 degradation. J Gen Virol. 2015;96(Pt 4):887–92.
 47. Kane JR, Stanley DJ, Hultquist JF, Johnson JR, Mietrach N, Binning JM, 
Jonsson SR, Barelier S, Newton BW, Johnson TL, et al. Lineage‑specific 
viral hijacking of non‑canonical E3 Ubiquitin ligase cofactors in the 
evolution of Vif anti‑APOBEC3 activity. Cell Rep. 2015;11(8):1236–50.
 48. Ai Y, Zhu D, Wang C, Su C, Ma J, Ma J, Wang X. Core‑binding factor 
subunit beta is not required for non‑primate lentiviral Vif‑mediated 
APOBEC3 degradation. J Virol. 2014;88(20):12112–22.
 49. Han X, Liang W, Hua D, Zhou X, Du J, Evans SL, Gao Q, Wang H, Viqueira 
R, Wei W, et al. Evolutionarily conserved requirement for core binding 
factor beta in the assembly of the human immunodeficiency virus/sim‑
ian immunodeficiency virus Vif‑cullin 5‑RING E3 ubiquitin ligase. J Virol. 
2014;88(6):3320–8.
 50. Münk C, Zielonka J, Constabel H, Kloke BP, Rengstl B, Battenberg 
M, Bonci F, Pistello M, Lochelt M, Cichutek K. Multiple restrictions 
of human immunodeficiency virus type 1 in feline cells. J Virol. 
2007;81(13):7048–60.
 51. Stern MA, Hu C, Saenz DT, Fadel HJ, Sims O, Peretz M, Poeschla EM. 
Productive replication of Vif‑chimeric HIV‑1 in feline cells. J Virol. 
2010;84(14):7378–95.
 52. LaRue RS, Lengyel J, Jonsson SR, Andresdottir V, Harris RS. Lentiviral Vif 
degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host 
and is capable of cross‑species activity. J Virol. 2010;84(16):8193–201.
 53. Zielonka J, Bravo IG, Marino D, Conrad E, Perkovic M, Battenberg M, 
Cichutek K, Münk C. Restriction of equine infectious anemia virus by 
equine APOBEC3 cytidine deaminases. J Virol. 2009;83(15):7547–59.
 54. Binka M, Ooms M, Steward M, Simon V. The activity spectrum of Vif 
from multiple HIV‑1 subtypes against APOBEC3G, APOBEC3F, and 
APOBEC3H. J Virol. 2012;86(1):49–59.
 55. Sonnhammer EL, Koonin EV. Orthology, paralogy and proposed clas‑
sification for paralog subtypes. Trends Genet. 2002;18(12):619–20.
 56. Yoshikawa R, Izumi T, Yamada E, Nakano Y, Misawa N, Ren F, Carpenter 
MA, Ikeda T, Münk C, Harris RS, et al. A naturally occurring domes‑
tic cat APOBEC3 variant confers resistance to FIV infection. J Virol. 
2015;90(1):474–85.
 57. Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of 
nondividing cells by optimized feline immunodeficiency virus vectors. 
Mol Ther. 2000;1(1):31–8.
 58. Bulliard Y, Turelli P, Röhrig UF, Zoete V, Mangeat B, Michielin O, Trono 
D. Functional analysis and structural modeling of human APOBEC3G 
Page 23 of 23Zhang et al. Retrovirology  (2016) 13:46 
reveal the role of evolutionarily conserved elements in the inhibition of 
human immunodeficiency virus type 1 infection and Alu transposition. 
J Virol. 2009;83(23):12611–21.
 59. Gohlke H, Hergert U, Meyer T, Mulnaes D, Grieshaber MK, Smits SH, 
Schmitt L. Binding region of alanopine dehydrogenase predicted by 
unbiased molecular dynamics simulations of ligand diffusion. J Chem 
Inf Model. 2013;53(10):2493–8.
 60. Widderich N, Pittelkow M, Höppner A, Mulnaes D, Buckel W, Gohlke 
H, Smits SH, Bremer E. Molecular dynamics simulations and structure‑
guided mutagenesis provide insight into the architecture of the cata‑
lytic core of the ectoine hydroxylase. J Mol Biol. 2014;426(3):586–600.
 61. Gehring WJ. The homeobox in perspective. Trends Biochem Sci. 
1992;17(8):277–80.
 62. Suspene R, Henry M, Guillot S, Wain‑Hobson S, Vartanian JP. Recovery of 
APOBEC3‑edited human immunodeficiency virus G → A hypermutants 
by differential DNA denaturation PCR. J Gen Virol. 2005;86(Pt 1):125–9.
 63. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, 
Münk C, Nymark‑McMahon H, Landau NR. Species‑specific exclusion of 
APOBEC3G from HIV‑1 virions by Vif. Cell. 2003;114(1):21–31.
 64. Bähr A, Singer A, Hain A, Vasudevan AA, Schilling M, Reh J, Riess M, 
Panitz S, Serrano V, Schweizer M, et al. Interferon but not MxB inhibits 
foamy retroviruses. Virology. 2015;488:51–60.
 65. Huthoff H, Malim MH. Identification of amino acid residues in 
APOBEC3G required for regulation by human immunodeficiency virus 
type 1 Vif and Virion encapsidation. J Virol. 2007;81(8):3807–15.
 66. Letko M, Booiman T, Kootstra N, Simon V, Ooms M. Identification 
of the HIV‑1 Vif and human APOBEC3G protein interface. Cell Rep 
2015;13(9):1789–99.
 67. Vasudevan AA, Smits SH, Hoppner A, Häussinger D, Koenig BW, Münk 
C. Structural features of antiviral DNA cytidine deaminases. Biol Chem. 
2013;394(11):1357–70.
 68. Kouno T, Luengas EM, Shigematsu M, Shandilya SM, Zhang J, Chen L, 
Hara M, Schiffer CA, Harris RS, Matsuo H. Structure of the Vif‑binding 
domain of the antiviral enzyme APOBEC3G. Nat Struct Mol Biol. 
2015;22(6):485–91.
 69. Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, Kurosawa 
T, Yokomaku Y, Yamane T, Watanabe N, Suzuki A, et al. The APOBEC3C 
crystal structure and the interface for HIV‑1 Vif binding. Nat Struct Mol 
Biol. 2012;19(10):1005–10.
 70. He Z, Zhang W, Chen G, Xu R, Yu XF. Characterization of conserved 
motifs in HIV‑1 Vif required for APOBEC3G and APOBEC3F interaction. J 
Mol Biol. 2008;381(4):1000–11.
 71. Zhang W, Huang M, Wang T, Tan L, Tian C, Yu X, Kong W, Yu XF. Con‑
served and non‑conserved features of HIV‑1 and SIVagm Vif medi‑
ated suppression of APOBEC3 cytidine deaminases. Cell Microbiol. 
2008;10(8):1662–75.
 72. Baig TT, Feng Y, Chelico L. Determinants of efficient degradation of 
APOBEC3 restriction factors by HIV‑1 Vif. J Virol. 2014;88(24):14380–95.
 73. Marin M, Golem S, Rose KM, Kozak SL, Kabat D. Human immunode‑
ficiency virus type 1 Vif functionally interacts with diverse APOBEC3 
cytidine deaminases and moves with them between cytoplasmic sites 
of mRNA metabolism. J Virol. 2008;82(2):987–98.
 74. Richards C, Albin JS, Demir O, Shaban NM, Luengas EM, Land AM, 
Anderson BD, Holten JR, Anderson JS, Harki DA, et al. The binding inter‑
face between human APOBEC3F and HIV‑1 Vif elucidated by genetic 
and computational approaches. Cell Rep. 2015;13(9):1781–8.
 75. Salter JD, Morales GA, Smith HC. Structural insights for HIV‑1 therapeu‑
tic strategies targeting Vif. Trends Biochem Sci. 2014;39(9):373–80.
 76. Aydin H, Taylor MW, Lee JE. Structure‑guided analysis of the human 
APOBEC3‑HIV restrictome. Structure. 2014;22(5):668–84.
 77. Land AM, Shaban NM, Evans L, Hultquist JF, Albin JS, Har‑
ris RS. APOBEC3F determinants of HIV‑1 Vif sensitivity. J Virol. 
2014;88(21):12923–7.
 78. Siu KK, Sultana A, Azimi FC, Lee JE. Structural determinants of HIV‑1 
Vif susceptibility and DNA binding in APOBEC3F. Nat Commun. 
2013;4:2593.
 79. Ooms M, Letko M, Binka M, Simon V. The resistance of human 
APOBEC3H to HIV‑1 NL4‑3 molecular clone is determined by a single 
amino acid in Vif. PLoS One. 2013;8(2):e57744.
 80. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF. A single amino acid difference 
in human APOBEC3H variants determines HIV‑1 Vif sensitivity. J Virol. 
2010;84(4):1902–11.
 81. Lavens D, Peelman F, Van der Heyden J, Uyttendaele I, Catteeuw D, 
Verhee A, Van Schoubroeck B, Kurth J, Hallenberger S, Clayton R, et al. 
Definition of the interacting interfaces of Apobec3G and HIV‑1 Vif using 
MAPPIT mutagenesis analysis. Nucleic Acids Res. 2010;38(6):1902–12.
 82. Tautz D, Domazet‑Loso T. The evolutionary origin of orphan genes. Nat 
Rev Genet. 2011;12(10):692–702.
 83. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, 
Shaw GM, Kappes JC. Emergence of resistant human immunodefi‑
ciency virus type 1 in patients receiving fusion inhibitor (T‑20) mono‑
therapy. Antimicrob Agents Chemother. 2002;46(6):1896–905.
 84. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O’Brien WA, Ratner L, Kap‑
pes JC, Shaw GM, Hunter E. Sensitivity of human immunodeficiency 
virus type 1 to the fusion inhibitor T‑20 is modulated by coreceptor 
specificity defined by the V3 loop of gp120. J Virol. 2000;74(18):8358–67.
 85. Loewen N, Barraza R, Whitwam T, Saenz DT, Kemler I, Poeschla EM. FIV 
Vectors. Methods Mol Biol. 2003;229:251–71.
 86. Morris KV, Gilbert J, Wong‑Staal F, Gasmi M, Looney DJ. Transduction 
of cell lines and primary cells by FIV‑packaged HIV vectors. Mol Ther. 
2004;10(1):181–90.
 87. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH. 
Complementation of vif‑defective human immunodeficiency virus 
type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol. 
1995;69(7):4166–72.
 88. Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ. Aberrant Gag 
protein composition of a human immunodeficiency virus type 1 vif 
mutant produced in primary lymphocytes. J Virol. 1995;69(7):4582–6.
 89. Jaguva Vasudevan AA, Perkovic M, Bulliard Y, Cichutek K, Trono 
D, Häussinger D, Münk C. Prototype foamy virus Bet impairs the 
dimerization and cytosolic solubility of human APOBEC3G. J Virol. 
2013;87(16):9030–40.
 90. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy 
and high throughput. Nucleic Acids Res. 2004;32(5):1792–7.
 91. Stamatakis A, Ludwig T, Meier H. RAxML‑III: a fast program for maximum 
likelihood‑based inference of large phylogenetic trees. Bioinformatics. 
2005;21(4):456–63.
 92. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and 
post‑analysis of large phylogenies. Bioinformatics. 2014;30(9):1312–13.
 93. Shimodaira H, Hasegawa M. Multiple comparisons of log‑likeli‑
hoods with applications to phylogenetic inference. Mol Biol Evol. 
1999;16(8):1114.
 94. Huson DH, Bryant D. Application of phylogenetic networks in evolu‑
tionary studies. Mol Biol Evol. 2006;23(2):254–67.
 95. Stern A, Doron‑Faigenboim A, Erez E, Martz E, Bacharach E, Pupko T. 
Selecton 2007: advanced models for detecting positive and purify‑
ing selection using a Bayesian inference approach. Nucleic Acids Res. 
2007;35(Web Server issue):W506–11.
 96. Pond SK, Muse SV. Site‑to‑site variation of synonymous substitution 
rates. Mol Biol Evol. 2005;22(12):2375–85.
 97. Šali A, Blundell TL. Comparative protein modelling by satisfaction of 
spatial restraints. J Mol Biol. 1993;234(3):779–815.
 98. Miao Z, Cao Y, Jiang T. RASP: rapid modeling of protein side chain 
conformations. Bioinformatics. 2011;27(22):3117–22.
 99. Xu D, Zhang Y. Improving the physical realism and structural accuracy 
of protein models by a two‑step atomic‑level energy minimization. 
Biophys J. 2011;101(10):2525–34.
 100. Gerber PR, Muller K. MAB, a generally applicable molecular force field 
for structure modelling in medicinal chemistry. J Comput Aided Mol 
Des. 1995;9(3):251–68.
